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ABSTRACT 
Genetic defects of erythrocyte transport proteins cause disorders of red blood cell 
volume that are characterized by abnormal permeability to the cation and, 
consequently, by changes in red cell hydration. Within this group of hereditary 
anemias we focused on familial pseudohyperkalemia and dehydrated hereditary 
stomatocytosis. The main aims of the project thesis are to study both the molecular 
genetics and the pathogenic mechanisms of these two disorders. 
Isolated Familial Pseudohyperkalemia (FP) is a dominant red cell trait 
characterized by cold-induced ‘passive leak’ of red cell K+ into plasma. The 
causative gene of this condition is ABCB6, encoding an erythrocyte membrane 
ABC transporter protein bearing the Langereis blood group antigen system.  
Dehydrated hereditary stomatocytosis (DHS) is an autosomal dominant congenital 
hemolytic anemia with moderate splenomegaly and often compensated hemolysis. 
Red cells are characterized by cation leak of the red cell membrane, reflected in 
elevated sodium content, decreased potassium content, elevated MCHC and MCV, 
and decreased osmotic fragility. The majority of symptomatic DHS cases reported 
to date have been associated with gain-of-function mutations in the 
mechanosensitive cation channel gene, PIEZO1. 
Our study started with the recruitment of 97 patients affected by both FP and DHS 
from 41 unrelated families of Italian and foreign countries. 
Regarding familial pseudohyperkalemia, analyzing three new families, we reported 
the first functional characterization of ABCB6 mutants, including homozygous 
mutation V454A, heterozygous mutation R276W, and compound heterozygous 
mutations R276W and R723Q. All these mutations are annotated in public 
databases, suggesting that FP could be common in the general population. Indeed, 
we identified variant R276W in one of 327 random blood donors (0.3%). 
Measurement of cation flux demonstrated greater loss of K+ or Rb+ from HEK-293 
cells expressing ABCB6 mutants than from cells expressing ABCB6 WT. The 
R276W/R723Q mutations elicited greater cellular K+ efflux than did the other 
mutants tested. 
Regarding dehydrated hereditary stomatocytosis by whole exome sequencing 
analysis of two previously undiagnosed DHS families we identified the second 
causative gene of DHS, the KCNN4 gene, encoding the Gardos channel (KCa3.1), 
the erythroid Ca2+-sensitive K+ channel of intermediate conductance. We 
characterized the expression of KCNN4 in the mutated patients and during 
erythroid differentiation of hematopoietic progenitor cell CD34+ and K562 cells. We 
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also analyzed KCNN4 expression during mouse embryonic development. Finally, 
we demonstrated that the mutations in KCNN4, as for PIEZO1, cause a gain of 
function, by increasing potassium efflux.  
Moreover, by analysing the genotype of the patients here collected, we 
characterized a new interesting mutation in PIEZO1, that is a duplication of two 
aminoacids localized in the pore of the channel, found in two families with different 
phenotype. We further analysed the modified effect of an additional PIEZO1 
missense variant carried by the family exhibiting the more severe phenotype. We 
found that the missense variant co-inherited with the duplication cause an 
augmented potassium efflux.  
In conclusion, ABCB6 missense mutations in FP erythrocytes show elevated K+ 
efflux. The patients are present at moderate frequency in the blood donor 
population. Storage of blood of these patients leads to significantly increased K+ 
levels, with serious clinical implications for neonates and infants receiving large-
volume transfusions of whole blood. Genetic tests for FP could be added to blood 
donor pre-screening. Further study of ABCB6 function and trafficking could be 
informative for the study of other pathologies of red blood cell hydration. 
The identification of KCNN4 mutations in DHS patients supports recent studies that 
indicate it plays a critical role in normal erythrocyte deformation in the 
microcirculation and participates in maintenance of erythrocyte volume 
homeostasis. The characterization of PIEZO1 and KCNN4 mutations in DHS has 
contributed to the understanding of DHS pathogenesis that will be useful for the 
prognosis, the management, the follow-up, and the treatment of these patients. 
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1. Background 
 
1.1 Red blood cell membrane: genesis, structure and function 
During its long life span of 120 days, the red blood cell (RBC) is forced to cross the 
pores of splenic sinusoids thousands of times. This cell has an ongoing relationship 
with the spleen that contributes to remodeling during the first week of its life, 
participating in the passage from reticulocyte to erythrocyte. Moreover the spleen 
plays a primary role in the removal of aged RBCs. In order to perform these 
journeys RBCs must possess and maintain a significant deformability. The main 
author of this property is certainly the membrane, that ensures both mechanical 
stability and deformability. After the first proposed model of the RBC membrane 
skeleton 36 years ago (Lux et al 1979), containing the core elements of the modern 
model, many additional proteins have been discovered during the intervening 
decades, and their structures and interactions have been defined (Mohandas et al 
2008; Lux 2016). RBC membrane is composed by a fluid double layer of lipids in 
which approximately 20 major proteins and at least 850 minor ones are embedded 
(Andolfo et al 2016). The membrane is attached to an intracellular cytoskeleton by 
protein-protein and lipid-protein interactions that confer the erythrocyte shape, 
stability and deformability. The transmembrane proteins have mainly a transporter 
function. However, several of these also have a structural function, usually 
performed by an intracytoplasmic domain interacting with cytoskeletal proteins. The 
lipid bilayer acts as a barrier for the retention of cations and anions within the red 
cells, while it allows water molecules to pass through freely. Human erythrocytes 
have high intracellular K+ and low intracellular Na+ contents when compared with 
the corresponding ion concentrations in the plasma. The maintenance of this cation 
gradient between the cell and its environment involves a passive outward 
movement of K+, which is pumped back by the action of an ATP-dependent 
Na+/K+ pump in exchange for Na+ ions. This protein belongs to a class of 
transmembrane proteins with a transport function (Figure 1.1). 
 
5 
 
 
Figure 1.1. Simplified cross-section of the erythrocyte membrane. The red blood cell membrane 
is composed of integral membrane proteins incorporated into a phospholipid bilayer. The network of 
cytoskeletal proteins is anchored to the membrane via several transmembrane proteins with a 
transport function: band 3, anion transporter; GLUT1, glucose and L-dehydroascorbic acid 
transporter; RhAG, gas transporter, in particular CO2; various cation pumps and transporters 
including, Na+-K+-ATPase, Ca++-ATPase, Na+-K+-2Cl− and Na+-Cl−, Na+-K+, K+-Cl− co-
transporters and Gardos channel. The most recently described proteins PIEZO1, KCNN4 and 
ABCB6, involved in the modulation of RBC membrane permeability, and their putative interactions are 
also shown. The relative positions of the proteins to each other within the various complexes are 
mostly unknown. The shapes of the major proteins are mostly imaginary.  
GPA, glycophorin A; Rh, Rhesus polypeptide; B-4.1, protein band 4.1; B-4.2, protein band 4.2; GPC, 
glycophorin C; RhAG, Rh-associated glycoprotein; RBC: red blood cells. *Proteins that are known to 
be affected by pathogenic mutations so far. 
 
The third and more important component of the RBC membrane is the 
cytoskeleton, a protein network that laminates the inner surface of the membrane. 
Spectrin a and β-chains, proteins 4.1, or 4.1R, and actin are the main components 
of this skeleton, maintaining the biconcave shape of the RBC. These components 
are connected to each other in two protein complexes; ankyrin and protein 4.1 
complex. The former is composed by band 3 tetramers, Rh, RhAG, CD47, 
glycophorin A and protein 4.2. Whereas the protein 4.1 complex is composed by 
band 3 dimers binding adducins a- and β-, glycophorin C, GLUT1 and stomatin 
(Figure 1.1). The ends of spectrin tetramers converge toward a protein 4.1 complex 
(junctional complex). Electron microscopy (EM) shows that this latter links the tail 
of six spectrin tetramers, forming a pseudo-hexagonal arrangement (Liu et al 
1987). Spectrin tetramers include anion transporters (band 3 or 
chloride/bicarbonate exchange). The capability of these transporters to form 
aggregates could define the half-life of RBCs, causing antibody binding and 
removal by the spleen. Defects that interrupt this vertical structure (spectrin-actin 
interaction) underlie the biochemical and molecular basis of hereditary 
 
6 
 
spherocytosis (HS), whereas defects in horizontal interactions (skeletal attachment 
to membrane proteins) cause hereditary elliptocytosis (HE). 
Membrane protein synthesis is an important part of the differentiation process of 
erythroid cells in bone marrow and it starts very early. Cell culture studies 
established that this production is asynchronous (spectrin production starts before 
the synthesis of other cytoskeletal components) and is quantitatively exuberant (the 
production of a-spectrin exceeds that of β-spectrin three or four times) (Chen et al 
2009). This pattern of production seems to play an important role in the genetics of 
both HS and HE: as a matter of fact only homozygous or double heterozygous 
defects of a-spectrin could cause HS; whereas the presence of hypomorphic 
alleles (such as a-LELY, Low expression Lyon) is completely asymptomatic. 
However, due to its limiting amount (with respect to a-spectrin), the deficiency of β-
spectrin causes HS in the heterozygous state as well. Band 3 and ankyrin 
synthesis are the latest to occur and they seem to play a critical role in assembly. 
Protein 4.1 and ankyrin are the last cytoskeletal protein components to continue to 
be synthesized and assembled. This is at least partly due to the fact that ankyrin 
and protein 4.1 mRNA persist late into erythropoiesis when the levels of the 
majority of cytoplasmic RNAs, including those for band 3 and spectrins, have 
declined precipitously (Andolfo et al 2016). 
 
1.2 Classification, diagnostic criteria and epidemiology of erythrocyte 
membrane defect-related anemias 
From the genetic standpoint, 15 different types of anemias due to RBC membrane 
defects are currently included in the Online Mendelian Inheritance in Man (OMIM) 
compendium of human genes and genetic phenotypes (Table 1.1). Of note, the 
gene mutations identified so far refer only to a restricted number of patients; 
indeed, the molecular defect is still unknown for several patients. We can divide 
RBC membrane disorders into two main subgroups: (i) structural defects, and (ii) 
altered permeability of the RBC membrane. The first subgroup comprises: HS, HE, 
hereditary pyropoikilocytosis (HPP), and Southeast Asian ovalocytosis (SAO); the 
second subgroup contains: dehydrated hereditary stomatocytosis (DHS), 
overhydrated hereditary stomatocytosis (OHS), familial pseudohyperkalemia (FP), 
and cryohydrocytosis (CHC). 
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Table 1.1. Classification of HAMDs by OMIM database 
Disease 
symbol 
Phenotype 
Phenotype  
MIM number 
Gene 
location 
Inheritance 
HS1 Hereditary spherocytosis type 1 182900 
ANK1 
8p11.21 
AD 
HS2 Hereditary spherocytosis type 2 616649 
SPTB 
14q23.3 
AD 
HS3 Hereditary spherocytosis type 3 270970 
SPTA1 
1q23.1 
AR 
HS4 Hereditary spherocytosis type 4 612653 
SLC4A1 
17q21.31 
AD 
HS5 Hereditary spherocytosis type 5 612690 
EPB42 
15q15.2 
AR 
HE1 Hereditary elliptocytosis 1 611804 
EPB41 
1p35.3 
AD 
HE2 Hereditary elliptocytosis 2 130600 
SPTA1 
1q23.1 
AD 
HE3 Hereditary elliptocytosis 3 - 
SPTB 
14q23.3 
AD 
HPP Hereditary Pyropoikilocytosis 266140 
SPTA1 
1q23.1 
AR 
SAO Ovalocytosis Southeast Asian type 166900 
SLC4A1 
17q21.31 
AD 
OHS 
Overhydrated hereditary 
stomatocytosis 
185000 
RHAG 
6p12.3 
AD 
DHS1 
Dehydrated hereditary 
stomatocytosis  
with or without 
pseudohyperkalemia  
and/or perinatal edema 
194380 
PIEZO1 
16q24.3 
AD 
DHS2 
Dehydrated hereditary 
stomatocytosis 2 
616689 
KCNN4 
19q13.31 
AD 
FP Familial pseudohyperkalemia 2 609153 
ABCB6 
2q35-q36 
AD 
CHC Cryohydrocytosis 185020 
SLC4A1 
17q21.31 
AD 
AD, Autosomal dominant; AR, Autosomal recessive 
 
 
1.3 Hereditary anemias due to RBC structural defects 
1.3.1 Hereditary spherocytosis 
HS is the most common non-immune hemolytic anemia with a prevalence of 
1:2000-5000 in the Caucasian population (Bogardus et al 2012). This value is 
probably higher due to under-diagnosed mild/moderate forms. HS refers to a group 
of heterogeneous inherited anemias showing a broad spectrum of clinical severity, 
ranging from asymptomatic to severe transfusion-dependent forms, even within the 
same family. The intra-familial heterogeneity can be ascribed to the co-inheritance 
of genetic variants involved in erythrocyte defects themselves or in other disorders, 
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such as enzymopathies, thalassemias and Gilbert syndrome (Jamwal et al 2016). 
However, HS clinical findings are summarized by hemolytic anemia, jaundice and 
splenomegaly. Reticulocytosis (6-10% to 35% in severe cases), increased mean  
corpuscular Hb concentration (MCHC > 34.5g/dL), increased RBC distribution 
width (RDW >14), and normal or slightly decreased MCV are the main laboratory 
findings. Anemia in most patients is mild (Hb >11 g/dL) or moderate (Hb 8-11 g/dL), 
due to poorly compensated hemolysis (Gallagher 2013). Symptomless or mildly 
anemic patients are often diagnosed after hemolytic or aplastic crises, while in 
mildly affected women the condition often becomes evident during pregnancy, but 
transfusions are required only rarely. A small percentage of patients present a 
severe form (Hb 6-8 g/dL), which needs regular blood transfusions. One of the 
most common complications of chronic hemolytic anemia is cholelithiasis, which is 
more frequent in patients who co-inherited Gilbert Syndrome (Lee et al 2014). Of 
note, the co-inheritance of HS and Gilbert disease can be misdiagnosed as Crigler-
Najjar syndrome type II. The third component of the HS triad is splenomegaly, 
observed in almost all adult patients. The spleen enlargement is mild or moderate, 
rarely massive: only one patient with spontaneous rupture has been described 
(Berne et al 1997), while in few patients splenic infarction has been observed 
(Jones et al 2015; Suzuki et al 2007). Extramedullary erythropoiesis and iron 
overload can also be observed. Hemosiderosis is more relevant in transfusion- 
dependent patients or in those who have co-inherited mutations in the causative 
genes of hereditary hemochromatosis (Perrotta et al 2008). The diagnosis of HS is 
based on clinical features, positive familial history and the observation of a 
peripheral blood (PB) smear, in which a variable percentage of spherocytes, 
related to the degree of anemia, mushroom red cells, poikilocytosis, acanthocytes 
and ovalostomatocytes can be found (Figure 1.2) (Da Costa et al 2013). The 
diagnostic guidelines of HS from the British Committee for Standards in 
Haematology do not recommend any additional tests for patients with classical 
clinical features and laboratory data (Bolton-Maggs et al 2012). Whenever 
necessary, indirect tests can also be performed. Among these, the eosin-5′-
maleimide (EMA) binding test shows high sensitivity (92-93%) and specificity 
(nearly 99%), although a positive test can also be obtained in patients affected by 
related conditions, such as congenital dyserythropoietic anemia type II (CDA II) 
(King et al 2008). Additional tests, such as the osmotic fragility (OF) test, acidified 
glycerol lysis test (AGLT) and the pink test, exhibit lower sensitivity compared to 
the EMA test (68%, 61% and 91%,respectively). Nevertheless, the combination of 
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the EMA and pink tests or those of the EMA and AGLT tests improves the 
sensitivity to 99% and 100%, respectively (Bianchi et al 2012). Ektacytometry is a 
highly sensitive test of membrane deformability (Gallagher 2013). 
 
 
Figure 1.2. Flow diagram for the differential diagnosis of hemolytic anemias due to RBC 
membrane defects.  
The flow diagram shows the main steps for guiding the clinical suspicion toward the diagnosis of 
different subtypes of hereditary erythrocyte membrane disorders. First-, second-, and third-line 
investigations are also shown. The cut-off for the EMA binding test is still debated: currently, a test 
with a reduction of EMA binding > 21%, in comparison with controls, is defined positive, whereas a 
test with a reduction of EMA binding < 16% is considered negative. Values between 16-21% are not 
conclusive, although a cut-off of 11% has been proposed. Hb: hemoglobin; MCH: mean corpuscular 
hemoglobin; MCV: mean cellular volume; MCHC; mean corpuscular hemoglobin concentration; CBC: 
complete blood count; RBC: red blood cells; OHS: overhydrated hereditary stomatocytosis; DHS: 
dehydrated hereditary stomatocytosis; AD: autosomal dominant; AR: autosomal recessive; EMA: 
eosin-5-maleimide; SDS: Sodium dodecyl sulfate; NGS: next generation sequencing; RHAG: rhesus 
blood group associated glycoprotein. PB: peripheral blood.  
 
In HS the characteristic features of ektacytometry are: decreased DI max, in 
conjunction with a shift of the Omin point to the right (reduced surface to volume 
ratio), and a shift of the O' or hyper point to the left (increased dehydration of the 
red cells) (Figure 1.3) (Da Costa et al 2013).  
 
10 
 
 
Figure 1.3. Examples of ektacytometric curves of different hereditary erythrocyte membrane 
disorders.  
The ektacytometer is a laser diffraction viscometer that measures RBCs (red blood cells) 
deformability at constant shear stress as a continuous function of suspending Osmolarity. Three 
principal features of the osmotic gradient ektacytometry profiles are: the Omin point (red asterisk), 
which corresponds to the osmolarity at which 50% of the red cells are lysed in the classical osmotic 
fragility test and represents the surface area to volume ratio; the maximal deformability index (DImax, 
black asterisk) value, which represents the maximal cellular deformability of the red cell population; 
and the O' or hyper point (blue asterisk), which corresponds to the osmolarity at DImax/2, which 
reflects the hydration status of the red cells. Ektacytometric analysis of (A) HS, (B) OHS, (C) DHS1 
and (D) DHS2 patients are shown. The dotted line is those relative to the control subjects. HS: 
hereditary spherocytosis; OHS: overhydrated hereditary stomatocytosis; DHS1: dehydrated hereditary 
stomatocytosis 1; DHS2: dehydrated hereditary stomatocytosis 2. 
 
As a third-line of investigation, the analysis of major erythrocyte membrane 
proteins via SDS-PAGE still represents invaluable support for the identification of 
different subsets of HS patients; however, several subjects remain unclassified by 
this technique. However, the biochemical analyses may be of great use in the 
interpretation of NGS data in order to assess the pathogenicity of identified genetic 
variants. In HS, the phenotype variability is linked to different molecular defects. 
The increased membrane fragility is caused by heterogeneous molecular defects 
due to deficiency and/or dysfunction in erythrocyte membrane proteins, ankyrin 
(ANK1), a- and β-spectrin (SPTA and STPB), band 3 (SLC4A1), and protein 4.2 
(EPB42) (Andolfo et al 2016). Approximately 75% of HS cases exhibit an 
autosomal dominant (AD) pattern of inheritance, associated with mutations in 
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ANK1, SPTB, EPB42 and SLC4A1 genes. In the remaining 25% of patients 
autosomal recessive (AR) and de novo mutations were observed (Table 1.1). 
 
1.3.2 Hereditary elliptocytosis and pyropoikilocytosis 
HE is characterized by the presence of elliptical-shaped erythrocytes (elliptocytes) 
on the PB smear associated to variable clinical manifestations. The worldwide 
incidence of HE is 1:2000-4000 individuals, but it results higher in some African 
regions (1:100). The majority of patients present no anemia or hemolysis, and 
diagnosis is made incidentally, after worsening of anemia due to infections or after 
diagnosis in symptomatic relatives. Severe anemia was observed only in rare 
cases. A good indicator for the severity of the disease is the percentage of spectrin 
dimers. A subtype of HE is HPP, a rare severe hemolytic anemia characterized by 
poikilocytosis and fragmented erythrocytes, resulting in low MCV (50-60 fL) and 
microspherocytes. 16 HPP patients show marked splenomegaly, and splenectomy 
is therefore usually recommended. There is a strong association between HE and 
HPP. The main defect in HE erythrocytes is mechanical weakness or fragility of the 
erythrocyte membrane skeleton due to defective horizontal connections of 
cytoskeletal proteins, such as spectrin dimer-dimer interactions and spectrin-actin-
protein 4.1 at the junctional complex. For the main part, HE is inherited as AD 
disease, with rare cases of de novo mutations, whereas HPP patients exhibit an 
AR inheritance. HE can be due to mutations in EPB41, SPTA1 and SPTB genes 
that lead to serious damage in the association of spectrin dimers/tetramers 
(Iolascon et al 2013). Also, HE shows high inter- and intrafamilial phenotypic 
variability, due to the modifier alleles. One example is the a-LELY in the SPTA1 
gene, a hypomorphic haplotype composed of two variants, the missense 
Leu1857Val and the splicing variant in intron 45. This hypomorphic haplotype alone 
causes minimum damage in both heterozygous and homozygous states since the 
spectrin a chains are produced in excess (3- to 4- fold compared to β-chains); 
otherwise, when it is associated with a HE mutation in SPTA1, the resulting 
phenotype is severe, i.e. HPP (Table 1.1) (Iolascon et al 2013). 
 
1.3.3 Southeast Asian ovalocytosis 
SAO is a very common condition in the aboriginal peoples from Papua New 
Guinea, Indonesia, Malaysia, the Philippines and southern Thailand, in areas 
where malaria is endemic, with prevalence varying between 5% and 25%. Indeed, 
this condition offers protection against all forms of malaria (Iolascon et al 2013). 
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Despite the reduced in vitro deformability of SAO erythrocytes, patients are 
asymptomatic and the diagnosis is made accidentally as a result of a PB smear 
examination, showing the characteristic rounded elliptocytes (ovalocytes). 
However, in newborns it may manifest as hemolytic anemia and require 
phototherapy. SAO is an AD condition caused by the deletion of 27 nucleotides in 
the SLC4A1 gene, leading to the loss of the amino acids 400-408 of protein band 
3.2 The deletion is in linkage disequilibrium with the Memphis polymorphism 
(p.Lys56Glu) in SLC4A1 (Table 1.1). SAO erythrocytes show a slight loss of 
monovalent cations when exposed to low temperatures, with a reduction of anions 
flux. Thus, the condition may be classified as a genetic disease affecting the 
permeability of the RBC membrane. Despite the frequency of heterozygotes, only 
one case homozygous for the 27 nucleotide deletion has been described so far. 
This patient showed severe phenotype with intrauterine transfusions, transfusion 
dependent anemia and distal renal tubular acidosis due to the loss of band 3, 
which is also expressed in the kidneys (Picard et al 2014). 
 
1.3.4 Other conditions 
Erythrocyte abnormalities can also be observed in other hereditary and acquired 
conditions. For example, the autoimmune hemolytic anemias are characterized by 
shortened RBC survival due to the presence of auto-antibodies directed toward red 
cells, with a positive Coombs test. RBCs are typically coated with auto-antibodies 
and trapped by macrophages in the cords of the spleen. The interaction of trapped 
RBCs with splenic macrophages may result in phagocytosis of the entire cell or 
partial phagocytosis with the formation of spherocytes, present in the blood film 
(Packman et al 2015). Micro- and macrospherocytes, associated with increased 
osmotic fragility, were also seen in patients affected by chronic hepatitis C virus 
treated with protease inhibitors (telaprevir and boceprevir). In these patients 
oxidative stress, induced by drugs, damages membrane-cytoskeletal stability, 
reducing a- and β-spectrins (Lupo et al 2016). Alterations in the RBCs membrane 
are also present in neuroacanthocytosis, a heterogeneous group of diseases that 
include chorea-acanthocytosis, McLeod and Huntington's disease-like syndromes. 
These conditions are characterized by alterations of post-translational 
modifications, mostly phosphorylation, of erythrocyte membrane proteins and 
significant neurological symptoms (De Franceschi et al 2014). 
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1.4 Anemias due to altered permeability of RBC membrane 
1.4.1 Dehydrated hereditary stomatocytosis or xerocytosis 
HST includes both DHS and OHS, which show alteration of the RBC membrane 
permeability to monovalent cations Na+ and K+, with a consequent alteration of the 
intracellular cationic content and alterations of cell volume (Delaunay 2007). DHS 
is the most highly represented among HST, with an incidence of approximately 
1:50000 births. It is 10-20 times less frequent than HS, with which it may be, 
however, confused. Of note, based on our experience, the incidence of this anemia 
could be underestimated because it is often undiagnosed. The phenotype ranges 
from asymptomatic to severe forms, with massive hemolysis. Generally, DHS 
patients show hemolytic well-compensated anemia, with a high reticulocyte count, 
a tendency to macrocytosis and mild jaundice. The main characteristic of RBCs is 
cell dehydration caused by the loss of the cation content, with a subsequent 
increase of MCHC (>36 g/dL). At blood smear the stomatocytes, erythrocytes with 
a characteristic central mouth-shaped spot, are quite rare, which often makes 
diagnosis difficult. In addition, it may be difficult when the clinical picture is 
associated with pseudohyperkalemia and/or perinatal edema, in the so-called 
pleiotropic syndrome form (Grootenboer et al 2008; Delaunay 2004). For these 
reasons, the condition may be overlooked for years or decades before reaching a 
conclusive diagnosis. Osmotic gradient ektacytometry is a useful tool to diagnose 
this condition; it shows a leftward shift of the minimum in the deformability index 
(Omin) at low osmolarities, as well as a decrease in DImax (Figure 1.3). DHS 
patients also exhibit a tendency toward having iron overload, regardless of the 
transfusion regimen or splenectomy (Syfuss et al 2006). The study of the iron 
metabolism in this condition is an open and interesting field of investigation, 
enabling the discovery of new drugs to treat the iron overload. DHS is inherited as 
an AD trait. The candidate gene locus was first localized at 16q23-24 (Carella et al 
1998; Grootenboer et al 2000). Several years later, PIEZO1 was identified as the 
causative gene of both isolated and syndromic forms of DHS1 by exome 
sequencing (Table 1.1) (Zarychanski et al 2012; Andolfo et al 2013). PIEZO1 
encodes a mechanoreceptor, an ion channel activated by pressure. This protein 
has been identified in the RBC membrane, and in mice it has been shown to form a 
tetramer of about 1.2 million daltons; it is therefore the largest ion channel identified 
to date, and moreover it regulates mechanotransductive release of ATP from 
human RBCs (Coste et al 2010; Ge et al 2015; Cinar et al 2015). The identified 
mutations are missense and mainly located in the highly conserved C-terminus of 
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the protein, recently described to form the pore of the channel (Coste et al 2015). 
Several electrophysiology studies demonstrated that the mutations cause a gain-
of-function phenotype with delayed inactivation of the channel (Andolfo et al 2013; 
Bae et al 2013) suggesting increased cation permeability leads to DHS erythrocyte 
dehydration (Figure 1.4).  
 
 
Figure 1.4. Cation channel activity in on-cell patch recordings of a DHSt red cells.  
(A) Representative graphs of channel activity in on-cell patches from an unrelated normal cell (above) 
and a DHSt red cell from patient SF. (B) NPo of channel activity in DHSt red cells from patient SF (n 5 
4), from an unrelated volunteer (Control, n 5 3) and from patient SF in the presence of pipet GsMTx-4 
(2.5 mM; n 5 3); *P , .05. (C) I-V curve of a representative on-cell patch record from a DHSt red cell of 
patient SF. 
 
Recently, a novel gene, KCNN4, has been identified as causative of a second form 
of DHS, named DHS2, in six different families (Table 1.1) (Rapetti-Mauss et al., 
2015; Andolfo et al., 2015; Glogowska et al., 2015). The KCNN4 gene encodes the 
Gardos channel, a widely expressed Ca2+-dependent K+ channel of intermediate 
conductance that mediates the major K+ conductance of erythrocytes (Andolfo et al 
2015; Andolfo et al 2016). Mutated KCNN4 channels showed a higher current 
compared to WT resulting from changes in the open probability, in the trafficking, 
and in the unitary conductance of the channel. This is suggestive of the pathogenic 
mechanism associated with several mutations affecting PIEZO1. In addition, this 
observation could suggest that PIEZO1 and the Gardos channel might act in the 
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same stretch-induced cation pathway involved in cell volume homeostasis. Unlike 
DHS1, patients affected by DHS2 show a normal pattern of ektacytometry analysis 
(Figure 1.3), whereas they exhibit iron overload similar to that in DHS1 patients 
(Rapetti-Mauss et al 2015; Andolfo et al 2015; Glogowska et al 2015). 
HST can also be associated with band 3 mutations, characterized by the 
conversion of band 3 from an anion exchanger to a cation transporter (Iolascon et 
al 2009). 
 
1.4.2 PIEZO1 
PIEZO1 is a cation selective channel activated by mechanical force (Coste et al 
2012; Kim et al 2012). It conducts all monovalent cations (Na+ , K+ , Li+ , Cs+ ) 
and also divalent cations, such as Ba2+, Ca2+, Mg2+ and Mn2+ 
(Gnanasambandam et al 2015). Its spatial organization has recently been solved 
and it appears to function as a trimer whose shape looks like a three-blade 
propeller (Ge et al 2015). Each subunit is structurally divided in 3 parts across the 
plasma membrane. The first consists of a large extracellular domain composed of 
the N terminal part of the protein (blade). The second region consists of the C-
terminal extracellular domain (CED), a membrane spanning domain with 14 a-
helices (the CED is located between helix 13 and helix 14 which is the inner helix 
facing the transport site); and third, an intracellular domain containing the C 
terminus (Figure 1.5). In addition to its role in RBC, PIEZO1 plays an important role 
in the vascular and renal systems (Bae et al 2013b). In 2012 and 2013, 3 different 
groups described mutations in PIEZO1 as the cause of HX in several unrelated 
families (Zarychanski et al 2012; Andolfo et al 2013). The substitutions in the 
mutated form of this protein consist of missense or truncating modifications that 
cluster in two hot spots located in the highly conserved C terminus pore module of 
the channel (Bagriantsev et al 2014; Ge et al 2015). For several mutations, the 
mutated channel has been demonstrated to exhibit greater activity and a slower 
rate of inactivation (Bae et al 2013b). The longer open state of the channel should 
drive an excess of K+ efflux and hence excess water loss. Beside its role in HX, 
defects in PIEZO1 have also been shown to result in congenital lymphatic 
dysplasia with the description of loss of function mutations (Fotiou et al 2015). This 
finding may be related to the fact that foetal oedema without anaemia has been 
reported several times in patients with HX (Andolfo et al 2013), and to the role of 
PIEZO1 in the alignment of vascular endothelium and proper blood vessel 
formation (Ranade et al 2014). 
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Figure 1.5. Models of human PIEZO1.  
Predicted membrane topology models of PIEZO1 (UniProt accession number 
Q92508) were created using Swiss-Prot prediction tools. The locations of PIEZO1 
mutations identified in DHS are indicated. 
 
1.4.3 KCNN4 
The Gardos channel The Gardos channel (KCNN4, KCa31, SK4, IK1) is a Ca2+ 
activated K+ channel of intermediate conductance (Andolfo et al 2016). This 
channel has been extensively studied in red cells, where it has been shown to 
decrease cell volume, but also in other cells, such as activated T- and B-cells, 
macrophages, microglia, vascular endothelium and epithelia, where it is involved in 
many physiological and pathological mechanisms. Consequently, it is considered 
as a potential target for therapeutic approaches in various diseases like sickle cell 
anaemia, asthma, atherosclerosis, kidney fibrosis and autoimmunity 
(Christophersen et al 2015). The Gardos channel is comprised of 4 identical 
subunits, each of which is encoded by a single gene, KCNN4, and consists of 6 
transmembrane domains and a pore region between transmembrane domain 5 and 
6 (Figure 1.6) (Maher et al 2003). In steady state conditions, the Gardos channel is 
inactive. Its function is not fully elucidated in mature normal erythrocytes; however 
it is thought to be one of the major players in the RBC volume changes (Thomas et 
al 2011). Under stimulation, such as external stress, intracellular Ca2+ increases 
and then interacts with Calmodulin molecules that are bound tightly on each of the 
four channel subunits of the Gardos channel. Interaction between Calmodulin and 
Ca2+ results in the opening of the channel and rapid K+ and water efflux leading to 
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erythrocyte dehydration and shrinkage, a mechanism referred to as the Gardos 
effect (Maher & Kuchel 2003).  
 
 
Figure 1.6. Structure of the KCNN4 channel. 
Structure of the KCNN4 channel consisting of six transmembrane domains, a pore 
region (P) between S5 and S6, and calmodulin interacting with the channel’s 
intracellular COOH terminus. 
 
In HX, the R352H mutated Gardos channel is more sensitive to Ca2+ activation, 
permits an increased efflux of K+ and remains open and active during a prolonged 
period when compared to the normal channel, leading to excessive RBC 
dehydration (Rapetti-Mauss et al 2015). A total of 7 independent families have 
currently been described with HX and mutations in the Gardos channel (Andolfo et 
al 2015; Glogowska et al 2015; Rapetti-Mauss et al 2015). Recurrent mutations in 
only 2 different sites account for all cases, the first one being located in the 
Calmodulin binding region of the channel (R352H) and the other one in the pore-
forming region (V282M/E). In one case, channel mutation occurred de novo, 
strongly suggesting, together with the recurrence, that the residue is, in itself, a hot 
spot for mutation. Pathophysiological mechanism for HX. Hyper-activation of either 
PIEZO1 or the Gardos channel leads to similar clinical phenotypes, strongly 
suggesting that both channels act together to shrink RBC volume under 
mechanical stress. It is likely that hyperactivity of the Gardos channel is 
responsible for K+ and water efflux, either because of an activating mutation in 
Gardos channel or because of mutations in PIEZO1 that would increase 
intracellular Ca2+ level and subsequently activate Gardos channel. However, 
PIEZO1 is more selective to K+ than it is to Ca2+ and mutations that prolong the 
conductive state of the channel (Albuisson et al 2013) are expected to increase the 
K+ leak through PIEZO1, independent of an eventual activation of the Gardos 
channel due to increased Ca2+ permeability. Further research on ion selectivity of 
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mutated PIEZO1 is necessary to fully understand its involvement in red cell 
dehydration. Although both the PIEZO1 and Gardos channels are expressed in 
other tissues, dysfunction of these proteins leads to defects only in circulating cells 
such as RBC. This suggests that compensatory mechanisms might take place 
specifically in the other tissues where these proteins are expressed. 
 
1.4.4 Overhydrated hereditary stomatocytosis 
OHS is a very rare subtype among HST, with 20 cases reported overall worldwide. 
Contrary to DHS, RBCs are hydrated due to an increase, from 20 to 40 times, in 
the loss of cations (Andolfo et al 2016) OHS is associated with more severe 
phenotypes compared to DHS. In addition to reticulocytosis, it is characterized by a 
sharp increase in MCV (>110 fL) and decreased MCHC (24-30 g/dL). The number 
of stomatocytes is usually much higher than that observed in DHS. The causative 
gene of this condition is RHAG, encoding the Rh-associated glycoprotein (RhAG) 
which acts as an ammonia channel (Table 1.1) (Andolfo et al 2016). Stomatin has 
been found at low or absent levels in OHS patients, but no mutations have been 
found in the encoding gene so far. Moreover, a complex syndrome named 
stomatin-deficient cryohydrocytosis has been described. It is characterized by 
mental retardation, seizures, cataracts and massive hepatomegaly. Recently, this 
syndrome was associated with mutations in SLC2A1 that cause both loss of 
glucose transport and a cation leak (Andolfo et al 2016). 
 
1.4.5 Familial pseudohyperkalemia and cryohydrocytosis 
FP and CHC are additional forms of stomatocytosis. FP is not associated with 
hemolytic anemia and stomatocytes are rarely observable on PB smear. 
Conversely, CHC patients show hemolytic anemia of variable degrees (Stewart et 
al 1979). RBCs from FP patients exhibit a loss of K+ at low temperatures (<37°C, 
mostly 8-10°C), but not at 37°C. In CHC the main feature is the temperature 
dependence of the loss of cations: instead of being around 8-10°C, the minimum is 
approximately 23°C. The gene responsible for FP was mapped at 2q35-q36,55 
(Carella et al 2004) and later identified in the ABCB6 gene (Andolfo et al 2013), 
encoding the homonymous protein, ABCB6. It belongs to the family of ABC 
transporters with the binding cassette for ATP, one of the most abundant families 
of integral membrane proteins. ABCB6 was previously identified as a porphyrin 
transporter, thus we now find that it is currently highly debated because several 
other studies identified its expression in the plasma membrane of RBCs and in the 
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endo-lysomal compartment, excluding the mitochondrial uptake of porphyrins 
(Andolfo et al 2016) Moreover, in erythrocyte membranes it bears the Langereis 
(Lan) blood group antigen system (Helias et al 2012; Kiss et al 2012). ABCB6 
expression increases during erythroid differentiation of CD34+ cells  (Andolfo et al 
2012). 
The ABCB6 missense mutations in FP does not alter mRNA or protein levels, or 
subcellular localization in mature erythrocytes or erythroid precursor cells, but are 
predicted to have a pathogenic consequence on protein function. CHC is due to 
mutations in the SLC4A1 gene; these are gain-of-function mutations, since they are 
able to transform the band 3 anion exchanger to a cation transporter (Table 1.1). 
 
1.4.6 ABCB6 
ABCB6 belongs to the family of ATP-binding cassette (ABC) transporters, one of 
the most abundant families of integral membrane proteins (Zutz et al 2009).The 
ABC transporters couple ATP binding and hydrolysis to the transport of 
endogenous and xenobiotic substrates across cellular membranes. ABCB6 is a 
member of the B (MDR/TAP) subfamily of ABC transporters best known as drug-
resistance genes, and it can form homodimers (Krishnamurthy et al 2006). 
Indeed, increased ABCB6 expression correlates with increased drug resistance in 
multiple cell lines (Szakacs et al 2004). A specific ABCB6 function was first 
described in Saccharomyces cerevisiae mutants lacking mitochondrial ABC 
transporter Atm1p (Mitsuhashi et al 2000). Complementation of Atm1p-deficient 
yeast with human ABCB6 rescued the phenotypic alterations, leading to the 
proposal that ABCB6 is the human ortholog of Atm1p (Mitsuhashi et al 2000). In 
2006, ABCB6 was shown to catalyze mitochondrial uptake of coproporphyrin III, as 
an important regulator of cellular porphyrin biosynthesis (Krishnamurthy et al 
2006). However, Tsuchida questioned the mitochondrial localization of ABCB6, 
providing evidence for its localization in endoplasmic reticulum and Golgi 
membranes, rather than in mitochondria (Tsuchida et al 2008). The observation 
of extra-mitochondrial localization has been extended by the study of dominantly 
inherited ABCB6 mutations in patients with ocular coloboma and dyschromatosis 
universalis hereditaria (Liu et al 2014; Wang et al 2012). Gene expression 
profiling studies of zebrafish blood formation mutants revealed ABCB6 among 
genes of the erythroid cluster (Weber et al 2015). ABCB6 was recently shown to 
carry the Lan (Langereis) blood group antigen system of the RBC plasma 
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membrane (Helias et al 2012). The asymptomatic Lan (-/-) carriers display a 
variety of recessive null mutations, all with red cells of normal phenotype (Helias 
et al 2012). Lan blood group mismatch can cause hemolytic transfusion reactions 
and hemolytic disease of the newborn. Kiss recently confirmed ABCB6 as a 
glycoprotein present in the membrane of mature erythrocytes and in exosomes 
released from reticulocytes during the final steps of erythroid maturation (Kiss et al 
2012). Knockdown studies demonstrated that ABCB6 function is not required for 
de novo heme biosynthesis in differentiating K562 cells, excluding this ABC 
transporter as an essential regulator of porphyrin synthesis.  
In the study of identification of ABCB6 as causative of FP, we confirm that 
ABCB6 is upregulated during erythroid differentiation and is localized at the plasma 
membrane in mature RBCs and in CD34+ during the erythroid differentiation 
(Andolfo et al 2013). Abcb6-/- mice exhibit a grossly normal phenotype, but lack 
ATP-dependent mitochondrial uptake of coproporphyrin III. ABCB6 deficiency 
upregulates heme and iron pathways that are necessary for normal development. 
However, in conditions of extreme demand for porphyrins (such as during 
phenylhydrazine stress), these adaptations appear inadequate, suggesting the 
importance of ABCB6 for optimal survival under these stress conditions (Ulrich et 
al 2012). 
 
1.5 Animal models 
Several animal models have been developed for the study of RBC defects (Table 
1.2). Concerning the mouse models, although the main stream of human hemolytic 
anemias caused by RBC membrane defects are inherited as AD, in mice these 
conditions are usually inherited as AR (Table 1.2). Recently, within hereditary 
stomatocytosis, mouse models of PIEZO1 were developed. Mice deficient in 
Piezo1 die in utero at mid-gestation due to defective vasculogenesis (Cahalan et al 
2015). Thus, another model of Piezo1 was developed by specific deletion in the 
hematopoietic system (Vav1-P1cKO mice). Hematological analysis of blood from 
Vav1-P1cKO mice revealed elevated MCV, MCH and reduced MCHC. RBCs 
exhibited increased osmotic fragility, demonstrating that Piezo1-deficient RBCs 
were overhydrated. At the moment a knock-in mouse model carrying missense 
mutations found in DHS1 patients doesn't exist; its creation will further elucidate the 
role of PIEZO1 in the hydration pathways of RBCs. Beyond mouse models, which 
in several cases don't recapitulate the main characteristics of human hematological 
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disease, a powerful model for the study of erythropoiesis is the zebrafish, Danio 
rerio, because of its small size, its ability to generate a large number of embryos, 
and its transparency that facilitates the visualization of erythroid cell migration 
(Kulkeaw et al 2012). Notably, the high conservation of hematopoietic genes 
among vertebrates and the ability to successfully transplant hematopoietic cells 
have enabled the establishment of models of human anemic diseases in zebrafish 
(Table 1.2). Recently, zebrafish models have also been created for PIEZO1. 
Morpholino-knockdown of Piezo1 expression in the Danio rerio was reported to 
result in severe anemia (Faucherre et al 2014). However, the phenotype observed 
in the morpholino-knockdown model was not present in an independent zebrafish 
model carrying a predicted truncated form of PIEZO1 (Table 1.2) (Shmukler et al 
2015). The debate on the phenotype observed in the two different models is still 
open (Shmukler et al 2016; Faucherre et al 2016). It is notable that patients with 
homozygous loss-of-function mutations in human PIEZO1 show lymphatic 
dysplasia and an asymptomatic, fully compensated, very mild hemolytic state of 
incomplete penetrance (Fotiou et al 2015). In conclusion, both mouse and 
zebrafish models appear not to better recapitulate the human pathogenesis, but 
they are useful to study the function of newly identified proteins such as PIEZO1. 
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Table 1.2. Animal models for the study of RBC membrane defects  
Organism Mutant 
Altered 
gene 
Type of alteration Phenotype 
PUBMED 
ID
§
 
Mus 
musculus 
ja/ja SPTB Deficiency of β-spectrin 
Severe hemolytic anemia, reticulocytosis 
7937844 
 sph/sph SPTA Deficiency of α-spectrin 11920196 
 Nan KLF1 Missense E339D 
Neonatal anemia; in adult mice, hemolytic anemia with decreased 
RBCs, hematocrit, Hb, and elevated zinc protoporphyrin levels 
20691777 
 
ENU-
generated 
ANK1 Nonsense E924X 
Heterozygous mice: low MCV, elevated RBC counts, reticulocytosis, 
reduced EMA intensity, and increased osmotic fragility 
21193012 
 wan Slc4a1 Premature stop codon 
Homozygous mice: severe anemia with marked anisocytosis and 
spherocytosis at the PB smear 
15070709 
 sph
Dem
/sph
Dem 
 SPTA 
In frame deletion of 46 amino 
acids that alters spectrin 
dimer/tetramer stability  
Increased MCV, decreased MCHC, marked reticulocytosis (50%). 
PB smears: elliptocytes, spherocytes and occasional poikilocytes, as 
seen in human severe HE  
11154235 
 Vav1-P1cKO  PIEZO1  
Gene deletion in the 
hematopoietic system 
Elevated MCV, MCH and reduced MCHC. RBCs exhibit increased 
osmotic fragility  
26001274 
Danio 
rerio 
merlot  EPB41 Mutation 
Spiculated RBC membranes; hemolytic anemia, cardiomegaly, 
splenomegaly 
12183387  
 Morpholino PIEZO1  knockdown of gene expression Severe anemia with swollen, fragile and spherocytic RBCs 23872304 
 ZFN knockout PIEZO1  Frameshift in the exon 8 No anemia or dysmorphic erythrocyte morphology 26294733 
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2. AIMs of the study 
 
This PhD program is focused on the study of molecular genetics and pathogenetic 
mechanism of two inherited haemolytic anemias: Isolated Familial 
Pseudohyperkalemia (FP) and Dehydrated hereditary stomatocytosis (DHS). Both 
conditions are included in the group of hereditary membrane defects of RBCs 
characterized by alterations of the ionic transport across the cellular membrane. 
Three years ago our group identified disease causing genes of both the conditions: 
ABCB6 for FP and PIEZO1 for DHS (Andolfo et al 2012; Andolfo et al 2013).  
 
The aims of this program are:  
AIM 1: Functional characterization of ABCB6 mutants to understand the 
pathogenetic mechanism of FP and its implication in blood transfusion 
AIM 2: Identification of other causative gene/s of DHS by whole exome sequencing 
in those cases negative for mutations in PIEZO1 
AIM 3: Functional characterization of PIEZO1 and KCNN4 mutations to understand 
the molecular pathogenesis of DHS. 
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3. Materials and Methods 
 
3.1 Collection of all patients 
Up to now we enrolled the largest cohort of patients with DHS and FP: 97 affected 
subjects from 41 unrelated families of Italian and foreign countries. This is 
associated with clinical record data and DNA/RNA/plasma membrane protein bank. 
For all patients we have recruited hematological and iron metabolism parameters. 
 
3.2 FP patients 
Three new patients with FP from three independent pedigrees were enrolled in this 
study (see Table 4.1 in the “Results” section), and blood samples were obtained 
from affected patients. Whenever possible, relatives were also investigated. 
Diagnosis was based on history, clinical findings, laboratory routine data, 
peripheral blood smear, and genetic testing. Information about every clinical 
characteristic was not available for all cases. A cohort of 327 blood donors from the 
blood transfusion center of the Cardarelli Hospital in Naples was enrolled to 
undergo genetic screening for the ABCB6 mutations found in this study. 
Collection of patient data and samples was obtained by the clinicians responsible 
for patient care with informed consent according to the Declaration of Helsinki and 
with approval by local university ethical committees. 
 
3.2.1 Whole exome sequencing (WES) of FP Irish family  
Blood was obtained for genetic analysis from affected and unaffected family 
members of the Irish family and from healthy controls, with signed informed 
consent according to the Declaration of Helsinki. Blood collection was according to 
protocols approved by local university ethics committees. Genomic DNA was 
prepared from peripheral blood with the Wizard Genomic DNA purification kit 
(Promega, Milano, Italy). Five μg of DNA from two affected and two unaffected 
members of DHS Irish family was diluted in 700 μl of Nebulization buffer (Illumina, 
San Diego, CA) and sheared by nebulizers (Invitrogen, Carlsbad, CA) into 
fragments of 200–400 bp in length (Bioanalyzer 2100, Agilent, Santa Clara, CA). 
Sheared samples purified by QIAquick spin columns (Qiagen, Hilden, Germany) 
were processed for library preparation (Illumina protocol), omitting size-selection of 
adapter-ligated fragments prior to capture. After several cycles of PCR 
amplification, 500 ng of DNA from the resulting libraries was hybridized to the bait 
set from the SureSelect Human All Exon Kit (Agilent, Santa Clara, CA, USA) at 
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65°C for 24 h. Hybrid capture with streptavidin-coated Dynal magnetic beads 
(Invitrogen, Carlsbad, CA) was performed as manufacturer’s protocol. Captured 
samples were further purified through Agencourt AMPure XP beads and subjected 
to PCR amplification. All samples at each step of library preparation were 
quantified by Bioanalyzer 2100 (Agilent). Individual sample libraries were NaOH-
denatured and loaded onto one lane of an Illumina Flowcell v4. DNA clusters were 
generated through a one-step workflow on the Cluster Station using TruSeq PE 
Cluster Kit v5 (Illumina, San Diego, CA). A PhiX control library added to each 
sample at 1% volume served as internal control. Sequencing was performed on the 
Illumina Genome Analyzer IIx platform as paired-end 100-bp reads according to 
the manufacturer’s protocol. An exome capture was considered successful if >80% 
of the target regions were covered with a high quality genotype. Reads were 
aligned to the most recent version of human genome (GRCh37/hg19) using the 
BWA software package v0.5.  
 
3.2.2 Sanger sequencing analysis of ABCB6 gene 
The search for mutations was performed by direct sequencing, using 75 ng 
genomic DNA. All exons and flanking splice junctions of the ABCB6 gene were 
amplified by PCR in a 25 μl volume with Master Mix 2X (Promega). Oligonucleotide 
primers were designed by the program Primer3 v.0.4.0. Integrity of PCR products 
was checked by agarose gel electrophoresis. Direct sequencing was performed 
using the BigDye® Terminator Cycle Sequencing Kit (Applied Biosystems, 
Branchberg, NJ, USA) and a 3730 DNA Analyzer (Applied Biosystems). Missense 
substitution mutations in ABCB6 (Q9NP58) were evaluated by Poly-Phen-2 
(http://genetics.bwh.harvard.edu/pph2/index.shtml) and SIFT (http://sift.jcvi.org/) 
online tools. 
 
3.2.3 ABCB6 screening in donor blood subjects 
Mutation screening for ABCB6 variants R276W, V454A, and R723Q in a population 
of 327 blood donors was performed by amplification-refractory mutation system 
(ARMS) analysis, using allele specific tetra-primer ARMS-PCR primers designed 
by PRIMER1 (http://primer1.soton.ac.uk/primer1.html). 
 
3.2.4 Bioinformatic modeling of ABCB6 protein structure 
To assess the potential effects of the identified mutations on protein structure, we 
generated 3D structural models of dimeric human WT ABCB6 residues 231–827 
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and the corresponding regions of FP mutant ABCB6 polypeptides V454A, R276W, 
and R723Q. Sequences were aligned in ClustalW2. MODELLER v9.913 was used 
for homology modeling in both inward- and outward-facing 6 conformations. The 
best five structural models with lowest objective function values (as implemented in 
MODELLER) were subjected to energy minimization in GROMACSv4.5.414. 
Structural models were converged using steepest descent energy minimization 
with 1,000 steps of step size 0.01 nm. Stereochemical quality of each energy-
minimized structure was assessed by PROCHECK15. The average of three 
models of highest stereochemical quality was chosen for ABCB6 structural models. 
3D structural models were visualized and aligned using MolMol16 and PyMOL 
1.5.0.4 (Schrödinger, LLC). 
 
3.2.5 Molecular cloning of ABCB6 and site-directed mutagenesis 
To detect and determine the inheritance pattern of the two mutations in patient 
Cardiff 2, the DNA fragment encompassing the two mutations R276W and R723Q, 
of ABCB6 was PCR amplified and cloned into PCR Cloning Vector pSC-A-amp/kan 
(StrataClone PCR Cloning Kit, Agilent). Point mutations c.1123 C>T, p.R375Q; 
c.1361T>C; p.V454A; c.826G>T; p. R276W; c.2168G>A; p.R723Q; c.1124 G>A; 
p.R375W were introduced into pcDNA3.1-ABCB6 with the QuikChange kit 
(Stratagene, La Jolla, CA). The integrity of the complete ABCB6 coding region was 
confirmed by sequencing after mutagenesis. Primers sequences are available 
upon request. 
 
3.2.6 Cell culture and transfection assay for ABCB6 
Human HEK-293 cells were maintained in DMEM medium (Sigma) supplemented 
with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL 
streptomycin (all from Life Technologies), in a humidified 5% CO2 atmosphere at 
37°C. pcDNA3.1-ABCB6-WT and pcDNA3.1-ABCB6 mutant constructs (5μg) were 
transfected into HEK-293 cells using X-tremeGENE HP DNA Transfection Reagent 
(Roche, Indianapolis, IN, USA). To phenocopy the heterozygous genotypes, cells 
were transfected with 2.5μg of WT pcDNA3.1-ABCB6-WT plus 2.5μg of pcDNA3.1-
ABCB6 mutants R375Q, p.R276W or R375W. 
For the compound heterozygous genotypes, cells were transfected with 2.5μg 
pcDNA3.1-ABCB6-R276W plus 2.5μg pcDNA3.1-ABCB6-R723Q. For the 
homozygous genotype, cells were transfected with 5μg pcDNA3.1-ABCB6-V454A. 
After 72 hrs, cells were harvested for analysis. 
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3.2.7 Immunofluorescence analysis of ABCB6 
HEK-293 cells (2x106) on coverslips were transfected with ABCB6 cDNAs as 
previously described (Andolfo, 2012). After 72 hrs, cells were fixed, and 
immunostained with anti-FLAG (1:200; F3165, Sigma) and anti-WGA (Wheat Germ 
Agglutinin, Alexa Fluor 555 Conjugate, Life Technologies). Secondary antibodies 
for FLAG (Alexa Fluor 488 goat anti-mouse; Life Technologies) were incubated at 
1:200 dilution in PBS for 30 min at room temperature. Nuclei were stained with 1 
μg/ml DAPI in PBS for 15 min at room temperature. The coverslips were mounted 
in 50% glycerol (v/v) in PBS and imaged by Zeiss LSM 510 Meta confocal 
microscope equipped with an oil immersion plan Apochromat 63× objective 1.4 NA, 
Green channel excitation of Alexa488 by the argon laser 488 nm line was detected 
with the 505-550 nm emission bandpass filter. Red channel excitation of Alexa546 
by the Helium/Neon laser 543 nm line was detected with the 560-700 nm emission 
bandpass filter (using the Meta monochromator). Blue channel excitation of DAPI 
by the blue diode laser 405 nm line was detected with the 420-480 nm and 
emission bandpass filter. 
 
3.2.8 Measurements of K+ fluxes in red blood cells of blood donor carrying 
ABCB6 R276W variant 
Blood samples from the donor carrying the ABCB6 R276W mutation and from two 
controls obtained from the transfusion center of the Cardarelli Hospital (Naples) 
were stored four weeks at 4°C in Citrate Phosphate Dextrose Solution (CPD) as 
anticoagulant, under blood bank conditions. During the four weeks' storage, plasma 
potassium levels were measured in triplicate by atomic absorption spectroscopy 
(ANALYST 2000, Perkin-Elmer). The RBCs were gently washed with a buffer 
containing (in mM) 150 choline chloride, 1mM MgCl2, 10mM Tris MOPS, then 
lysed for intracellular K measurement by atomic absorption spectroscopy. The free 
Hb levels were measured to evaluate the degree of hemolysis as for K. 
 
3.2.9 Measurements of ouabain-plus-bumetanide-resistant Rb+ and K+ fluxes 
in ABCB6 transfected HEK-293 cells 
HEK-293 cells at 72 h post-transfection were maintained for 8h under shear stress 
(rotary shaking at 70 rpm 30°C) in a K+-free medium containing (in mM) 140 NaCl, 
5 mM RbCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, with added 10 μM ouabain 
and 10 μM bumetanide. At the end of the incubation, cell viability was determined 
by trypan blue staining and medium was removed for extracellular K determination. 
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Cells were gently washed in buffer containing (in mM) 150 choline chloride, 1mM 
MgCl2, 10mM Tris MOPS, then lysed for intracellular Rb measurement. Cell Rb 
content and medium K content were determined in triplicate by atomic absorption 
spectroscopy (ANALYST 2000, Perkin-Elmer) as previously described (De 
Franceschi et al 2007). 
 
3.2.10 RNA isolation, cDNA preparation and quantitative qRT-PCR 
Total RNA was extracted from cell lines and peripheral blood samples from 
patients and healthy controls using Trizol reagent (Life Technologies). Synthesis of 
cDNA from total RNA (2 μg) was performed using Super Script II First Strand kits 
(Life Technologies). Quantitative RT PCR (qRT-PCR) was by the SYBR-green 
method using the ABI PRISM 7900HT Sequence Detection system. Relative gene 
expression was calculated using the 2(-ΔCt) method, where ΔCt indicates the 
differences in the mean Ct between selected genes and the internal control 
(GAPDH or β-actin). Sequences of the qRT-PCR primers designed for each gene 
using Primer Express 2.0 (Life Technologies). 
 
3.2.11 Immunoblotting 
Total cell lysates (80 μg protein) electrophoresed on SDS-polyacrylamide gels 
were electroblotted onto polyvinylidene difluoride membranes (BioRad, Milan, 
Italy), incubated with the following antibodies: anti-FLAG (1:500; F3165, Sigma), 
anti-β-actin antibody (1:1000; Sigma, used as loading control), then imaged with 
HRP-conjugated anti-rabbit Ig (1:5000) (GE Healthcare, UK) and enhanced 
chemiluminescence substrate (Supersignal West Pico Chemiluminescent 
Substrate Kit, ThermoScientific, Miami USA). Labeled bands were visualized and 
densitometric analysis performed with the BioRad Chemidoc using Quantity One 
software (BioRad). 
 
3.2.12 Statistical analysis 
Data are presented as means ± standard error of the mean (s.e.m.). Statistical 
significance was calculated using the Mann-Whitney test and Student’s t test. 
Correlation analysis was calculated using Spearman’s rank correlation coefficient 
and Pearson’s correlation coefficient. P < 0.05 was considered as statistically 
significant. 
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3.3 DHS patients recruitment for the identification study of new causative 
gene/s 
Fifteen subjects from two independent families, previously screened for PIEZO1 
mutations, were enrolled in this study, an Italian family from Naples (family NA) and 
an American family from Worcester (family WO). The clinical data of the index 
cases are described in Table 4.5 (see “Results” section) as obtained by the 
clinicians responsible for patient care, and with the approval of local university 
ethical committees. All blood samples were obtained with informed consent. The 
diagnosis of DHS was based on history, clinical findings, routine laboratory data, 
peripheral blood smear, and genetic testing. DNA was obtained for genetic analysis 
from affected and unaffected family members, and from healthy blood donors after 
signed informed consent, according to the Declaration of Helsinki, and as approved 
by local university ethical committees. 
 
3.3.1 Whole exome sequencing and sequencing analysis of KCNN4 gene 
WES analysis was performed as described in paragraph 3.2.1. The search for 
mutations in KCNN4 gene was performed by direct sequencing, as already 
described for ABCB6 gene in the paragraph 3.2.2. Missense substitution mutations 
in KCNN4 (O15554) were evaluated by the aforementioned online tools, Poly-
Phen-2 and SIFT. Genotyping was also performed by sequencing KCNN4 cDNA 
prepared by RT-PCR from whole blood (see paragraph 3.3.4) from family WO 
members III.5, III.6, III.11, IV.5, IV.10, and IV.14. 
 
3.3.2 Isolation and erythroid differentiation of CD34+ hematopoietic 
progenitor cells 
Peripheral blood was collected from four healthy volunteers (with consent 
according to Declaration of Helsinki) and processed within 24 h. Mononuclear cells 
were isolated using Ficoll-Hypaque (1.077–0.001 kg/L; Sigma-Aldrich, Milan, Italy). 
The remaining RBCs were lysed by resuspension of the cell pellets in lysis buffer 
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). CD341 cells were isolated by 
positive selection using the miniMACS immunomagnetic isolation system (Miltenyi 
Biotec, Glodbach, Germany), with >95% yield. These CD34+ cells were cultured at 
105 cells/mL in a-MEM (GIBCO, Grand Island, NY) supplemented with 30% FBS 
(GIBCO) and with 2 mM L-glutamine, 1 mM hydrocortisone, 0.1 mM 
mercaptoethanol, 1% bovine serum albumin (BSA) in deionized water, 10 U/mL 
Penicillin/Streptomycin (Pen/Strep), 25 µg/mL gentamycin, (Sigma, St. Louis, MO). 
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To induce erythroid differentiation of CD34+ cells, 10 U/mL recombinant human 
erythropoietin (rHuepo, Janssen-Cilag, Milan) was added to complete a-MEM 
medium, and cells were incubated 14 days at 378C in a 5% CO2 atmosphere. Cell 
samples were collected on days 0, 7 and 14 for determination of cell number and 
viability (Trypan Blue exclusion). Erythroid differentiation was assessed by 
expression of transferrin receptor-1 (CD71) and glycophorin A (CD 235A) as 
detected by FACS. 
 
3.3.3 K562 cell culture and erythroid differentiation  
K562 human myeloid leukemia cells (ATCC, Manassas, VA) were maintained in 
RPMI medium (Sigma, Aldrich) supplemented with 10% FBS (Sigma, Milan) and 
Pen/Strep (Sigma, Milan) and grown in humidified 5% CO2 at 37°C. 50 µM hemin 
(Sigma, Milan) was added to the culture medium to initiate erythroid differentiation 
(2-3x105/mL). Samples were collected at specific time points: before hemin addition 
(0D), and at days 4 and 6 after hemin addition. Erythroid differentiation was 
assessed by FACS detection of transferrin receptor 1 (CD71) and glycophorin A 
(CD235A).  
 
3.3.4 RNA isolation, cDNA preparation, and quantitative qRT-PCR.  
Total RNA was extracted from cell lines and peripheral blood samples from 
patients and healthy controls using Trizol reagent (Life Technologies). cDNA 
synthesis from total RNA (2 µg) was performed using Super Script II First Strand 
kits (Life Technologies). Quantitative RT-PCR (qRT-PCR) was by the SYBR-green 
method, following standard protocols with an Applied Biosystems ABI PRISM 
7900HT Sequence Detection system. Relative gene expression was calculated 
using the 2(-DCt) method, where DCt indicates the differences in the mean Ct 
between selected genes and the normalization control (GAPDH or b-actin). qRT-
PCR primers for each gene were designed using Primer Express software version 
2.0 (Life Technologies). 
 
3.3.5 Red blood cell membrane preparation.  
Peripheral blood from healthy controls was lysed by three freeze-thaw cycles in 
5mM KH2PO4 containing protease inhibitor cocktail (Calbiochem, Merck KGaA, 
Darmstadt, Germany, set III, animal-free). The membrane fraction was sedimented 
by lysate centrifugation at 36,000 g for 20 min at 48C. Membrane extracts were 
loaded on SDS-polyacrylamide gels as described for total cell lysates. 
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3.3.6 Mouse embryo collection and Immunoblotting 
C57BL6/J mouse embryonic tissues were collected at E9.5, E10.5, E12.5, E15.5 
as previously described (Andolfo et al 2013). Immunoblotting. Total cell lysates (80 
µg protein) were subjected to SDS-PAGE, transferred to polyvinylidene difluoride 
membranes (BioRad, Milan, Italy), then incubated with the following antibodies: 
polyclonal rabbit anti-ABCB6 (1:250; SAB1300078, Sigma, Milan, Italy), polyclonal 
rabbit anti-PIEZO1 (1:500; Proteintech 15939-1-AP), anti-EPB72 (1:200; GeneTex, 
CA), monoclonal anti-band3 (1:200, Santa Cruz Biotechnology, CA), monoclonal 
anti-b-actin antibody (1:1000; Sigma, used as loading control), and HRP-
conjugated anti-rabbit Ig (1:5000) (GE Healthcare, UK). Blots were incubated in 
enhanced chemiluminescence substrate (Supersignal West Pico 
Chemiluminescent Substrate Kit, Thermo- Scientific, Miami, USA). Labeled band 
visualization and densitometric analysis were by Chemidoc imager and Quantity 
One software (BioRad). 
 
3.3.7 Statistical analysis 
Data are presented as mean ± standard error (SE). Statistical significance was 
calculated using the Student’s t test and one-way ANOVA. P<0.05 was considered 
as statistically significant. 
 
3.4 DHS patients collection for PIEZO1 study 
Twelve subjects from two independent families, were enrolled in this study, an 
English family from Jersey island (family 1) and an Italian family from Bari (family 
2). The clinical data of the index cases were obtained by the clinicians responsible 
for patient care, and with the approval of local university ethical committees. All 
blood samples were obtained with informed consent. The diagnosis of DHS was 
based on history, clinical findings, routine laboratory data, peripheral blood smear, 
and genetic testing. DNA was obtained for genetic analysis from affected and 
unaffected family members, and from healthy blood donors after signed informed 
consent, according to the Declaration of Helsinki, and as approved by local 
university ethical committees.  
 
3.4.1 Direct sequencing of PIEZO1 
Genomic DNA preparation and sequencing analysis was performed as described 
elsewhere (paragraphs 3.2.2 and 3.3.1). In this case our primers were designed to 
avoid amplification of Piezo2 , Piezo1P1 and Piezo1P2 (Ensembl Gene ID 
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ENSG00000154864, ENSG00000233686, ENSG00000237121). Missense 
substitution mutations in PIEZO1 (Q92508) were evaluated by the aforementioned 
Poly-Phen-2 and SIFT programs.  
 
3.4.2 Cloning, site direct mutagenesis and transfection assay 
cDNAs encoding full-length wildtype PIEZO1 were cloned in pLVX-EF1α-IRES-
ZsGreen1 vector. The point mutations c.7473_7478dupGGAGCT, 
p.Glu2492_Leu2493dup and c.5591G>A, p.Arg1864His were introduced into 
pLVX-EF1α-IRES-ZsGreen1-PIEZO1 by site-directed mutagenesis. The constructs 
obtained were transfected into HEK-293 cells for 72h as for ABCB6 constructs (see 
paragraph 3.2.4).  
 
3.4.3 Measurements of ouabain-plus-bumetanide-resistant Rb+ and K+ fluxes 
in PIEZO1 transfected HEK-293 cells 
For the evaluation of ouabain-plus-bumetanide-resistant Rb+ and K+ fluxes in 
PIEZO1 transfected HEK-293 cells, we performed the same assays described for 
ABCB6 (see paragraph 3.2.9). 
 
3.4.4 Osmotic gradient ektacytometry 
Deformability of the RBCs of the patients and relative control subjects were 
evaluated by osmotic gradient ektacytometry using the Laser-assisted Optical 
Rotational Cell Analyzer (LORCA). 
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4. Results 
 
4.1 Functional characterization of ABCB6 mutations in FP 
4.1.1 Case Reports 
The Bolivian patient is a 41 year old female from a consanguineous family. Multiple 
outpatient blood samples indicated elevated plasma K+ (8.3 mmol/L). Renal and 
adrenal function and EKG were normal, as were hematological indices except for 
macrocytosis (MCV 95-98 fL; Table 4.1). Past medical history included premature 
menopause and migraines. Physical examination was unremarkable. 
Patient Cardiff-2 is a 35 year old female with a prior tentative diagnosis of 
hereditary spherocytosis with a positive family history, despite a normal red cell 
eosin maleimide (EMA) binding test. Outpatient values of plasma [K+] ranged 
between 8.0 and 8.6 mmolL, in contrast to hospital clinical values between 5.4 and 
5.9 mmol/L (Table 4.1). The patient had been under outpatient care for diabetes 
and other conditions since 1999. Her peripheral blood smear revealed 
polychromasia, target cells, and a few spherocytes. Past medical history included 
Irritable Bowel Syndrome, oophorectomy in 2007, splenectomy secondary to 
trauma in 2008, and diagnosis of depression in 2009. Medications included 
omeprazole, mebevirine and citalopram. Blood pressure was normal, as was the 
remainder of the physical exam. Absolute reticulocyte count was 176.0 x109 (4.10 
%) with mean reticulocytes volume of 118 fl (reference range 90-110 fl). 
The large Irish family was originally described by Stewart and colleagues18 as 
autosomal dominant dehydrated hereditary stomatocytosis (DHSt) with FP. The 
propositus developed several thrombotic episodes following splenectomy at age 40 
years. An increased passive K+ leak was noted (Table 4.1). 
The families Lille, Falkirk and East London were previously described (Andolfo et al 
2013). Affected individuals from Family Lille (of Flemish descent) presented with 
normal hematological indices except for a slightly elevated MCV. Affected from 
family FP Falkirk (of Pakistani origin) also presented with macrocytosis. Affected 
from family FP ‘‘East London’’ (of Bangladeshi origin) were anemic and 
hyperkalemic, but in the absence of reticulocytosis and jaundice were considered 
non hemolytic. 
None of the carriers had colobomatous abnormalities of iris or retina, also 
associated with missense ABCB6 mutations. Carriers were not tested for Lan (-/-) 
status, as this phenotype is caused by nonsense mutations that cause complete 
absence of ABCB6 polypeptide in circulating red cells.  
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Table 4.1. Clinical data of FP patients  
Family code  Ethnicity  Hb (g/dL)  MCV (fL)  MCH (pg)  
K
+ 
(mmol/L)  
(< 37°C)  
Normal range 
 
12-18 80-95 25-31 3.5-4.5 
Bolivian  
South 
America  
13 95-98  29.3 8.3-8.7  
Irish Ireland  14.8-15.8  95-98  33.7  6.7-7.6  
Cardiff-2  
United 
Kingdom 
11.9-12.3  116  32.3  8-8.6  
Lille # France  13.7  96  30.7  4-5.5  
Falkirk # Pakistani  11.3-14-7  81-105.5  34.3  7-8.2  
East London #  Bangladesh  12-14.2  97  32.6  7-13.7  
In bold are the previously unreported families included in this study. 
# These families was previously described (Andolfo, 2012).
 
 
4.1.2 ABCB6 mutational analysis in FP families and blood donor screening 
We sequenced the ABCB6 gene in two patients and one family with FP. In the 
Bolivian patient we found the homozygous mutation c.1361T>C; p.V454A, while in 
patient Cardiff-2 we found compound heterozygosity for the two mutations 
c.826G>T; p.R276W and c.2168G>A; p.R723Q (Table 4.2). Parents of both 
patients were unavailable for genetic analysis. To analyze the allelic pattern of the 
two mutations in patient Cardiff-2, we cloned the genomic region encompassing 
both ABCB6 variants (about 6 Kb) into a plasmid vector. DNA sequencing of this 
cloned region demonstrated that the two mutations are in trans in patient Cardiff-2. 
In the Bolivian patient, the presence of heterozygous SNPs excluded the possibility 
of a deletion within the region of the gene harboring the mutation. 
The Irish family originally diagnosed as DHS plus FP was at first mapped to 
chr.1619 but subsequent analysis of the PIEZO1 gene was negative. We therefore 
subjected the Irish family to WES analysis and identified ABCB6 variant c.826G>T; 
p.R276W, with subsequent confirmation by direct sequencing. Probably, there was 
a misassignment in the Irish pedigree linkage analysis, however, we cannot rule 
out the presence of intronic mutations that could explain epistasis between PIEZO 
and ABCB6. 
ABCB6 amino acid residues R276, R723 and V454 are conserved among all 
species analyzed and each have Polyphen2 scores of 1 (damaging) and SIFT 
scores of 0 (damaging). Each of the three FP mutations is annotated in public 
databases: 1000 Genomes (URL: http://browser.1000genomes.org) (Auton et al 
2015); NHLBI Exome Sequencing Project (URL: 
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http://evs.gs.washington.edu/EVS); Exome Aggregation Consortium (ExAC), 
Cambridge, MA (URL: http://exac.broadinstitute.org). Minor allele frequency (MAF) 
was 0.43% for V454A variant, 0.08% for R723Q, and 1.5% for R276W (Table 4.2 
and Table 4.3). 
The high frequency of the variants found in our patients prompted our genetic 
screening of a cohort of 327 blood donors. Of note, our analysis demonstrated the 
presence of variant R276W in 0.3% of this cohort (1/327) and the absence of the 
other two mutations V454A and R723Q, consistent with the MAF values reported to 
date. 
 
Table 4.2. Mutations found in FP patients  
Family 
code 
ABCB6 
mutations 
SNP ID MAF
§
 
PolyPhen-2/ 
SIFT scores 
References 
Bolivian 
c.1361T>C; 
p.V454A* 
rs61733629 0.001 (C) 0.996/0 
unpublished 
data 
Cardiff 2 
c.826C>T; 
p. R276W # 
c.2168G>A; 
p.R723Q # 
rs57467915 
rs14821104
2 
0.013 (T) 
0.001 (A) 
1/0 
0.997/0 
unpublished 
data 
Irish  
c.826C>T; 
p. R276W  
 
rs61733625 
 
 
0.013 (T) 
 
 
1/0 
 
unpublished 
data 
Lille 
c.1123 C>T; 
p. R375Q 
Not 
annotated 
- 1/0 Andolfo I. et al., 
2013 
Falkirk 
c.1124 G>A; 
p.R375W 
Not 
annotated 
- 1/0 Andolfo I. et al., 
2013 
East 
London 
c.1124 G>A; 
p.R375W 
Not 
annotated 
- 
1/0 Andolfo I. et al., 
2013 
*Mutations in homozygous state 
# 
The two mutations are in trans (see results section for details) 
§
Overall minor allele frequencies estimated from public databases (1000 genomes, 
ESP6500:European_American, CORNELL:AGI_ASP_population) 
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Table 4.3. Minor allele frequency of the ABCB6 variants here identified 
Database 
 
MAF (C) rs61733629 
(c.1361T>C; p.V454A) 
MAF (T) rs57467915 
(c.826G>T; p.R276W) 
MAF (A) rs148211042 
(c.2168G>A; p.R723Q) 
1000 genomes  
 
AFR 0/1322 1/1322 0/1322 
 
AMR 28/694 2/694 0/694 
 
EAS 1/1008 0/1008 0/1008 
 
EUR 0/1006 15/1006 1/1006 
 
SAS 0/978 1/978 0/978 
  ALL 29/5008; 0.58% 19/5008; 0.38% 1/5008; 0.02% 
NHLBI Exome Sequencing Project 
 
ESP6500:European_American  2/8600 114/8600 9/8600 
 
ESP6500:African_American  2/4406 17/4406 2/4406 
  ALL 4/13006; 0.03% 131/13006; 1% 11/13006; 0.08% 
Exome Aggregation Consortium (ExAC) 
  ALL 556/121256; 0.46% 632/33350; 1.9% 101/118464; 0.09% 
TOT (1000 genomes EUR+ESP6500:European_American+ ExAC)     
    618/144278; 0.43% 782/51364; 1.5% 113/136478; 0.08% 
Minor allele frequency of the variants identified in this study by the analysis of the public databases 1000 genomes, NHLBI Exome Sequencing Project and Exome Aggregation 
Consortium 
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4.1.3 ABCB6 mutations produce conformational changes in model structures 
To analyze potential consequences of the identified mutations on protein structure, 
we generated three-dimensional structural models of the (putatively dimeric) 
human WT ABCB6 residues 231- 10 827 and FP mutant polypeptides V454A, 
R276W, and R723Q (see Methods). Figure 4.1 shows 3D structural models of 
homodimeric WT ABCB6 in inward- and outward-facing conformations, highlighting 
sites of the homozygous and compound heterozygous FP missense mutations 
studied in this paper.  
 
 
Figure 4.1. Three-dimensional structural model of human ABCB6 mutations 
A. Three-dimensional structural model of a portion of homodimeric WT human ABCB6 in an inward-
facing conformation, as modeled on the aligned structure of M. musculus ABCB1A (PDB ID 3G5U). 
Monomer "a" (blue) of the homodimer represents ABCB6 aa residues 246 (N-) to 826 (- C), modeled 
on transmembrane helices 1-6 and NBD-1 of ABCB1A. Monomer "b" (pink) of the homodimer 
represents ABCB6 aa residues 237 (N’-) to 826 (-C’) modeled on ABCB1A transmembrane helices 7-
12 and its NBD-2. A surface model is superposed on the modeled polypeptide backbone ribbon 
structure. DHSt homozygous mutation site V454 (red spheres) is located between the membrane-
spanning helices and the NBDs, extending into the cytoplasmic vestibule of the dimer. Locations of 
 
38 
 
the compound heterozygous DHSt mutation sites R276 (magenta spheres)/R723 (olive spheres) are 
also shown. Arrows mark R276 of monomer A (located within the lipid bilayer) and R723 of monomer 
B (located within the NBD region in the cytoplasmic vestibule) of the dimer. The cavity (cyan spheres) 
at the intermonomeric interface outlines a postulated intra-membrane binding site for inhibitors of 
ABCB6-mediated porphyrin transport32, corresponding to the ABCB1 binding site of inhibitor 
QZ5933. In this and subsequent figures, each modeled ABCB6 monomer lacks its ectofacial N-
terminal tail and putative transmembrane spans 1-5, but includes putative transmembrane spans 6-11 
(TM) followed by the single nucleotide-binding domain (NBD). B. Transverse intra-membrane profile 
of the modeled inward-facing conformation of dimeric WT ABCB6 (as in panel A), with 
transmembrane helices rotated 90° around the axis shown. The view (lacking NBDs) looks outward 
from the ICL region, near the site of separated mutation site V454 (red) and farther from mutation site 
R276. The colored M1 domain helices are numbered 6-11 for ABCB6 monomer "a", and 6'-11' for the 
monomer "b" of the ABCB6 dimer. The arrows between helices 9 and 11 on one side, and helices 9' 
and 11' on the other side of the dimer mark the locations of side apertures proposed in mouse ABCB1 
to mediate hydrophobic drug uptake from the inner leaflet of the lipid bilayer for subsequent efflux 
from the cell, or for flippase-like transfer to the outer leaflet33. C. Three-dimensional structural model 
of homodimeric WT human ABCB6 in an outward-facing conformation, as modeled on the aligned 
structure of S. aureus Sav1866 (PDB ID 2HYD). The black oval encloses a central cavity at the inter-
monomeric interface, hypothesized to be an intra-membrane substrate binding site (as predicted for 
homodimeric Sav1866 of S. aureus34). Sites of homozygous and compound heterozygous mutations 
are shown using similar colored spheres as in panel A. D. Transverse intramembranous profile of the 
modeled outward-facing conformation of dimeric ABCB6 (as in panel C), with the transmembrane 
helices rotated 90o around the axis shown. The view (lacking 20 NBDs) looks inward from the 
extracellular edge of the outer leaflet of the membrane bilayer towards the approximated mutation 
sites V454 (at the level of the ICL region) and R276 (farther from the ICL region); color scheme as in 
panel C. Helices are labeled at ends closest to reader. The figure was prepared in PyMOL. 
 
Transverse views of intra-membrane bilayer regions are also presented. 
Comparison of WT with mutant models reveals that these mutations cause 
detectable conformational changes in regions on or near the missense substitution 
sites and at several more remote locations. In inward-facing models of 
homodimeric FP mutant V454A, the presence of Ala decreased by 2.3 Å the WT 
Cα-Cα interatomic distance between chain a residue 454 and chain b residue 454. 
In contrast, this change was minimal in the outward-facing conformation. The WT 
loop structure at aa 362-367 (packed adjacent to chain b residue 454 in the inward-
facing conformation) underwent a partial loop-to-helix transition in the homodimeric 
FP mutant V454A. Furthermore, the WT Cα-Cα interatomic distance between chain 
a residue 276 and remote chain b residue 723 decreased by 3.3 Å in the 
heterodimeric FP mutant R276W (chain a)/R723Q (chain b). The inward-facing 
conformation of this heterodimeric mutant also induced a loop-to-helix transition of 
chain a residues 408-409 at the ecto-end of a transmembrane helix and spatially 
adjacent to chain a missense substitution R276W. These amino acid substitutions 
also modestly alter interhelical distances near the mutation sites. Structural 
superposition of modeled WT polypeptide with each modeled mutant polypeptide 
reveals larger global structural deviations of mutant polypeptides in inward-facing 
than in outward-facing conformations (Table 4.4). Modeled heterodimeric 
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R276W/R723Q and homodimeric V454A mutant polypeptides exhibited greater 
structural deviation from WT than did homodimeric mutants R276W or R723Q 
(Table 4.4). 
 
Table 4.4. RMSD (Å) of superposed homology-modeled structures of the 
indicated patient-derived mutant ABCB6 dimers with the modeled wildtype 
ABCB6 homodimer 
 
Mutant ABCB6 Inward-facing Outward-facing 
V454A/V454A 1.48 0.81 
R276W
a
/R723Q
b
 1.88 0.58 
R276W
b
/R723Q
a
 1.57 0.74 
R276W/R276W 0.98 0.29 
R723Q/R723Q 1.17 0.79 
 
 
4.1.4 ABCB6 mutations cause no alteration of expression and cellular 
localization 
We modeled in vitro our patients' genotypes by transient transfection of WT and 
mutant ABCB6 expression plasmids into HEK293 cells. No significant differences 
between mutant and WT mRNA accumulation were evident 72h post-transfection 
(Figure 4.2A). Similarly, immunoblot analysis of heterologous FLAG tag confirmed 
equivalent accumulation of WT and mutant heterologous ABCB6 polypeptides 
(Figure 4.2B). 
We also tested effects of the mutations on ABCB6 membrane localization. 
Confocal microscopy analysis showed that all mutant polypeptides were expressed 
predominantly at the HEK-293 cell peripheral membrane, as demonstrated by 
colocalization of ABCB6-FLAG with the membrane marker lectin WGA wheat germ 
agglutinin (Figure 4.2C). 
 
 
40 
 
 
Figure 4.2. Expression and localization of ABCB6 mutants. 
A. ABCB6 mRNA levels in HEK-293 cells transfected with ABCB6 WT and mutants and empty vector 
as control. Values are means +/- s.e.m. of three independent experiments. *p < 0.001 WT, 
WT/R375Q, WT/R375W, WT/R276W, V454A/V454A, WT/R723Q, R276W/R723Q vs empty vector. B. 
Immunoblot showing ABCB6 Flag protein expression in HEK-293 cells transfected with FLAG tagged 
WT or mutant ABCB6 variants, or with empty vector as control and GAPDH as loading control. One of 
two similar experiments. C. Laser-scanning confocal microscopy images of HEK-293 cells transfected 
with WT or mutant ABCB6 variants, or with empty vector as control, analyzed by immunofluorescence 
with rabbit polyclonal anti-ABCB6 antibody (green) and WGA (membrane marker, staining both the 
nuclear envelope and the plasma membrane, red), with merged signal showing regions of 
colocalization in yellow (white arrows indicate the yellow regions in the merge). Cells were imaged 
with a Zeiss LSM 510 meta confocal microscope equipped with a 1.4 NA oil immersion plan 
Apochromat 100× objective. Intensity and contrast were adjusted with Axiovision software. 
Representative of three independent experiments. 
 
4.1.5 ABCB6 mutation R276W increases potassium efflux from red blood 
cells of a blood donor 
A blood sample from the blood donor heterozygous for ABCB6 variant and 
samples from two control donors were obtained and stored four weeks at 4°C 
under blood banking conditions. Extracellular and intracellular potassium levels 
were measured throughout the storage period. As shown in Figure 4.3A the 
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potassium efflux of blood donor after 28 days of storage is about 3.5 fold higher 
than the controls. Correspondingly, the intracellular RBCs potassium content is 
about 2.5 fold lower than the controls (Figure 4.3B). The degree of hemolysis over 
time for the blood samples was evaluated during storage by measurement of free 
Hb levels and was the same for three samples (data not shown). The data 
demonstrated that the physiological consequences of the blood donor's mutation is 
potassium efflux higher than in controls, and similar to that observed in FP patients. 
Moreover, immunoblot analysis on RBCs from the blood donor carrying R276W 
mutation demonstrated that the expression of ABCB6 does not differ between 
mutated donor and healthy controls (Figure 4.3A). 
 
 
Figure 4.3. ABCB6 protein expression and potassium efflux in red blood cells of blood donor 
carrying ABCB6 R276W variant. 
A. Plasma K content (expressed as mmol/L of whole blood) of blood from donor heterozygous for 
ABCB6 mutation R276W and from two healthy controls after 0D, 7D, 14D and 28D cold storage under 
blood banking conditions. * p < 0.01 donor vs two healthy controls. B. Intracellular K content 
(expressed as mmol/10
13
cells) of blood from donor heterozygous for R276W and from two healthy 
controls after 0D, 7D, 14D and 28D cold storage as in A. Ion contents in A and B were measured by 
atomic absorption spectrometry, and represent means +/- s.e.m. of 3 independent experiments. * p 
<0.01 donor vs two healthy controls . C. Immunoblot showing ABCB6 protein expression in RBC 
membranes from blood donor heterozygous for mutation R276W and pooled membranes from two 
healthy controls. β-actin was used as loading control. One of three similar experiments. 
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4.1.6 ABCB6 mutations cause cation flux alterations 
We next evaluated cell potassium content in HEK-293 cells over-expressing WT 
ABCB6 and different ABCB6 mutant variants. Preliminary experiments comparing 
cells maintained for 8h at 37°C or 30°C revealed no differences (data not shown). 
To mimic shipping conditions (critical for the serum [K+] alteration observed in the 
FP patients) we exposed HEK-293 cells over-expressing WT or mutant ABCB6 
variants to 0.12 g rotary shaking at 30°C for 8 h. As shown in Figure 4.4A, levels of 
extracellular K in media from HEK-293 cells over-expressing mutant ABCB6 
variants were significantly higher than for cells expressing WT ABCB6. 
Correspondingly, residual intracellular Rb content was significantly reduced in cells 
expressing three of the ABCB6 mutant genotypes, WT/R375Q, WT/R375W, 
V454A/V454A, as well as in the double mutant R276W/R723Q, compared to either 
WT ABCB6 or the other ABCB6 variants (WT/R273Q, WT/R276W) (Figure 4.4B). 
These data show different impacts of individual ABCB6 mutations on cellular K+ 
efflux insensitive to ouabain plus bumetanide, and an incrementally increased 
effect on cell K+ efflux of coexpression of the compound heterozygous ABCB6 
mutations R276W/R723Q. 
 
 
Figure 4.4. Analysis of potassium efflux of ABCB6 mutants. 
A. K content of extracellular medium sampled from cultures of cells overexpressing ABCB6 WT or 
ABCB6 FP mutants. Ion contents measured by atomic absorption spectrometry were expressed as 
mmol/mg protein. **p < 0.001 R276W/R723Q vs empty vector and WT; *p < 0.05 for WT/R375Q, 
WT/R375W, WT/R276W, V454A/V454A, WT/R723Q vs WT. B. Rb content of cells overexpressing 
ABCB6 WT and ABCB6 FP mutants, expressed as mmol/mg protein. Values in A and B are means 
+/- s.e.m. of four independent experiments. 
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4.2 KCNN4 gene identification as causative of DHS 
4.2.1 Cases report 
Proband II.3 from family NA, a 40-year-old Italian woman, was referred to the 
Medical Genetics service of University of Naples “Federico II” for moderate 
macrocytic anemia. She was born at term after an uncomplicated pregnancy to 
healthy non-consanguineous parents. Birth parameters were normal, and neonatal 
jaundice was treated with routine phototherapy. At the age of 7 years, she was 
referred for severe anemia after an acute tonsillitis. No transfusions were required. 
Blood examinations showed macrocytic anemia, with high indirect bilirubin and 
LDH, and negative Coombs test. Subsequent Hb levels remained <11 mg/dl, and 
hemolytic anemia was suspected. Measurement of red cell survival showed 
reduced lifespan with intra-marrow and intra-splenic hemolysis. Bone marrow 
revealed erythroid hyperplasia and dyserythropoiesis, leading to suspicion of 
atypical hereditary spherocytosis. At 21 years of age, the patient underwent 
splenectomy and cholecystectomy without improvement in her anemia. She 
remained transfusion-independent through two pregnancies with caesarean 
deliveries. The first pregnancy was complicated by fetal distress. The first male son 
(III.1) was born at term with normal birth parameters and jaundice with bilirubin 
levels of 21 mg/dl, treated with phototherapy for 7 days. Blood examinations 
showed normocytic anemia (Hb 9.2 g/dl) and thrombocytopenia. Echocardiography 
showed pulmonary stenosis and patent ductus arteriosus. Persistent normocytic 
anemia was observed in infancy. His persistent hemolysis resembled that of his 
mother. Mother (II.3) and son (III.1) were jointly referred to our Medical Genetics 
Unit for diagnostic assessment at the respective ages of 40 and 10 years. At 
physical examination, they presented jaundiced skin and sclerae with 
hepatomegaly. The male son (with mild intellectual disability and learning 
problems) had splenomegaly of 13 cm and cholelithiasis evident on ultrasound. 
Blood examination showed moderate macrocytic anemia with reticulocytosis in the 
mother and mild normocytic anemia in the child. Osmotic fragility and eosin-5-
maleimide (EMA) binding were normal in both patients. Plasma [K+] after overnight 
storage at 48C was not increased in either III.1 or II.3 as compared to healthy 
controls. Complete blood count data are shown in Table 4.5.  
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Table 4.5. Biochemical and hematological data of index cases from both 
families 
Parameters 
Normal 
range 
Family NA-II.3
#
 Family NA- Family WO- 
pre- post- III.1 IV.5 III.5 
Age (years) - 13 40 10 21 56 
Hb (g/dL) 11.5-16.5 10.4 9 10.5 12.5 13.3 
RBC (10
6
/µL) 3.8-5.8 3.0 2.5 3.6 3.3 3.9 
Hct (%) 37-47 30.5 28.5 31.3 35.6 37.0 
MCV (fL) 76-96 101 112 86 96 103 
MCH (pg) 27-32 34.3 35.4 28.8 33.7 - 
MCHC (g/dL) 30-35 34 31.6 33.5 36.1 - 
RDW (%) 11.5-15.5 - 14.5 4.1 14.7 - 
Retics % 0.5-2 11.8 17.7 6.3 12.2 6.5 
Retics abs count (x10
3
/µL) - 358 450 229 403 254 
PLT (10
3
/µL) 150-400 - 841 184 195 250 
WBC (10
3
/µL) 4-11 5.0 8.8 6.4 7.3 9.5 
Ferritin (ng/mL) 15-233 - 580 132 450 - 
Transferrin (mg/dL) 200-360 - 158 217 - - 
Serum iron (µg/dL) 37-145 - 230 127 - - 
Transferrin saturation (%) 15-45 - - 41 - - 
Total bilirubin (mg/dL) 0-1.2 3.88 4.3 4.7 12.1 1.7 
Conjugated bilirubin 
(mg/dL) 
0-3 0.55 0.7 0.5 - - 
Unconjugated bilirubin 
(mg/dL) 
<1 3.33 3.6 4.1 10.9 1.5 
LDH (IU/L) 240-480 - 260 579 650 280 
Haptoglobin (g/L ) 0.5-3.2 - <0.298 <0.298 <0.2 - 
HbA2 (%) 2-3.4 1.8 1.8 2.8 2.5 - 
HbF (%) <1 0.8 0.8 0.8 1.1 - 
K (mmol/L) 3.5-5.3 - 4.5 3.8 4.8 4.5 
Ca (mg/dL) 8.9-10.3 - 10.3 10.1 9.8 10.2 
# Splenectomized at age 40 
 
 
  
Peripheral blood smear of patient II.3 after splenectomy revealed several 
stomatocytes and anisopoikolocytosis; patient III.1 showed rare stomatocytes and 
anisopoikolocytosis (Figure 4.5A). Red cell ektacytometric analysis of post-
splenectomy patient II.3 showed a slight decrease of DiMax and Omin, with a slight 
right-shift. Patient III.1 showed a left-shifted curve indicating dehydration as usual 
for DHSt patients (Figure 4.5B). Patients in family WO exhibited well-compensated 
anemia with normal or near-normal hemoglobin levels and markedly increased 
reticulocytes. The osmotic gradient ektacytometry curve was left shifted. The 
deformability index remained within the normal range and O’ and Omin points were 
left-shifted as compared to the previously described DHS families harboring 
PIEZO1 gain-of function mutations. 
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Figure 4.5. Clinical and functional analysis of the KCNN4-R352H mutation.  
A. Peripheral blood smear examination of patients II.3 (post-splenectomy) and III.1 showed marked 
anisopoikolocytosis, with stomatocytes (arrows). B. The red cell deformability index (DI) was 
measured as a function of increasing bath osmolality in control red cells (dotted line) and red cells 
from III.1 (solid black line) and II.3 (solid gray line). Omin (dotted line on the left) represents the 
osmolality at which red cells are maximally swollen. O’ (dotted line on the right) indicates the 
osmolarity at which DI is half-maximal. The ektacytometry profile of II.3 (after splenectomy) shows 
diminished DImax; that of III.1 shows a left-shifted curve indicating deydratation.  
 
4.2.2 KCNN4 mutational analysis 
We performed WES analysis in both families presenting with clinical suspicion of 
DHS but without cosegregating PIEZO1 mutations. Affected subjects II.3 and III.1 
of the family NA revealed, the heterozygous missense mutation c.1055G>A, 
p.R352H (Figure 4.6A). This mutation was absent in the three unaffected subjects 
of the same family. This mutation occurred in a codon containing a CpG 
dinucleotide (ttcCGCcag), probably a mutational ‘hot spot’. The mutation was a de 
novo event in proband II.3, as it was absent in both parents (I.1 and I.2). In family 
WO, previously described in linkage with Chr.16 (Vantyghem et al 1991), we found 
the novel, heterozygous missense mutation c.844G>A, p.V282M. In this 
multigenerational family, we also extended analysis to additional affected subjects, 
confirming the segregation of the mutation (Figure 4.6B), which was absent from 
unaffected family members. Both of the reported KCNN4 mutations have 
Polyphen-2 score 1 (damaging) and SIFT score 0 (damaging). Neither mutation 
was found in the 1000 genomes database. 
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Figure 4.6. KCNN4 mutations 
A. Inheritance pattern of KCNN4-R352H mutation in the Italian family (NA). The mutation is a de novo 
event in propositus II.3. B. Inheritance pattern of KCNN4-V282M mutation in the American family 
(WO). 
 
4.2.3 Red cell membrane proteins in patients with KCNN4 mutations 
KCNN4 mRNA levels were unaltered in Family NA, as evaluated by qRT-PCR 
(Figure 4.7A). We further evaluated expression levels of several erythrocyte 
membrane proteins involved in other RBC defects, including band3 (AE1), ABCB6, 
PIEZO1 and EPB72. These were unaltered except for apparent reductions in 
PIEZO1 in affected subjects II.3, III.1 and in unaffected subject I.1 (Figure 4.7B). 
 
 
Figure 4.7. Characterization of KCNN4 and other RBCs gene products in family NA.  
A. KCNN4 mRNA level normalized to b-actin. No differences in KCNN4 expression of II.3 and III.1 
patients compared to healthy controls (HCs, 2.260.4; II.3, 2.060.3, P50.85; III.1, 2.760.9, P50.59) 
were observed. Data are presented as mean6SE of 3 experiments. P value has been calculated by 
Student t test. B. Immunoblot showing protein expression of PIEZO1, AE1, ABCB6, and EBP72 in 
human red blood cell membrane (80 µg) from patients II.3 and III.1 and unaffected family members I.1 
and I.2. Beta-actin is the loading control. One of three similar experiments. 
 
 
 
4.2.4 KCNN4 during erythroid differentiation and mouse embryogenesis 
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To investigate the role of KCNN4 in erythroid cells, we first examined KCNN4 
expression in an ex vivo model of erythroid differentiation. CD34+ cells isolated 
from the peripheral blood of healthy volunteers were induced to erythroid 
differentiation by 7 and 14 days of erythropoietin treatment, as detailed in Materials 
and Methods. As shown in Figure 4.8A, KCNN4 mRNA was significantly increased 
after 14 days of erythropoietin treatment (p = 0.002 for the trend). The same trend 
was observed in K562 cells induced to erythroid differentiation with hemin for 4 and 
6 days (p = 0.01 for the trend) (Figure 4.8B). We further analyzed Kcnn4 
expression during mouse embryonic development. We collected mouse embryos at 
E9.5, E10.5, E12.5, E15.5 for qPCR analysis of murine KCNN4 expression. Kcnn4 
mRNA abundance increased gradually from E9.5 to E15.5 (p = 0.0002; Figure 
4.8C). 
 
 
Figure 4.8. KCNN4 expression profiling during human erythroid differentiation and mouse 
embryonic development.  
A. KCNN4 mRNA levels (normalized to GADPH) in CD341 cells induced to erythroid differentiation by 
EPO at 0, 7 and 14 days. B. KCNN4 mRNA levels (normalized to GADPH) in K562 cells induced to 
erythroid differentiation by hemin at 0, 4 and 6 days (n536SE of 3). C. KCNN4 mRNA levels 
(normalized to GAPDH) in whole murine C57BL/6 embryos at E9.5, E10.5, E12.5, and E15.5. All P 
values are by Student T-test. 
 
 
 
4.3 Modifier effects of PIEZO1 variant on DHS phenotype 
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4.3.1 Cases report 
The case 1 is a 42 male years old form Jersey island that suffers from hemolytic 
anemia for over 20 years. Four of his five children also suffer from anemia (Figure 
4.9).  
 
 
Figure 4.9. Partial pedigree of the two families here analyzed. 
Left panel. Inheritance pattern of PIEZO1-E2492_L2493dup mutation in the family 1. The proband 1I 
is indicated by the arrow. Right panel. Inheritance pattern of PIEZO1-E2492_L2493dup mutation in 
the family 2. Proband 2II (indicated by the arrow) carried also the mutation R1864H in PIEZO1.  
 
He shows iron overload (negative for hemochromatosis), gallstones and 
splenomegaly with normal liver function. CBC shows decreased hemoglobin levels, 
increased MCV, MCHC and reticulocytes count (Table 4.7).  
 
Table 4.7. Blood count and laboratory data of the probands 
 
Proband 1 Proband 2 Normal range 
Age (years) 42 5   
Complete blood count        
RBC (10
6
/µL)  5.1 3.47 4.2-5.6  
Hb (g/dL)  9.5 9.1 12-17.5  
MCV (fL)  99 25.7 80-97  
MCHC (g/dL)  39.7 26.2 32-38  
Ret (%)  15 9.5 0.5-2  
Laboratory data        
Total bilirubin (mg/dL)  9.6 3.9 0.2-1.1  
Serum iron (µg/dL)  234 28 45-150  
Ferritin (ng/mL)  646 55 5-150  
Moreover, he shows high levels of bilirubin, serum iron and ferritin, trasferrin 
indicating iron overload saturation and LDH. The examination of peripheral blood 
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smear highlighted the presence of macrocytosis, polychromasia, schistocytes and 
some stomatocytes . The case number 2 is a child of ten years old. He present 
anemia from the birth. CBC shows decreased hemoglobin levels, normal MCV, 
elevated reticulocytes count (Table 4.7). He shows, gallstones and splenomegaly 
with high levels of bilirubin. The examination of peripheral blood smear highlighted 
the presence of polychromasia, schistocytes and some stomatocytes 
Ektacytometric analyses were performed for all the subjects here analyzed. As we 
can see, the curves showed a leftward shift of the bell-shaped curve for all the 
patients in respect to the healthy controls indicating dehydration of the RBCs 
(Figure 4.10). 
 
 
Figure 4.10. Ektacytometry analyses of the two families here analyzed. 
Panel on the left. The red cell deformability index (DI) was measured as a function of increasing 
osmolarity red cells from family 1 patients 1I, 2I, , 2III, 2IV and internal healthy controls of the same 
family. Panel on the right. The red cell deformability index (DI) was measured as a function of 
increasing osmolarity red cells from family 2 patient 2II and from healthy controls of the same family 
1I, 1II, and from a healthy control.   
 
4.3.3 PIEZO1 mutational analysis 
We sequenced PIEZO1 gene in both families presenting with clinical suspicion of 
DHS. Affected subjects of family 1 revealed, the heterozygous missense mutation 
c.7473_7478dupGGAGCT, p.E2492_L2493dup. This mutation was absent in the 
unaffected subjects of the same family. In family 2, we found the same duplication 
present in the family 1, but also an additional PIEZO1 mutation p.R1864H. The 
analysis of inheritance pattern in the proband of family 2 showed that Arg1864His 
is a de novo mutation. Cloning experiments showed the presence of both 
mutations  E2492_L2493dup and R1864H in cis in the proband of family 2. 
4.3.4 PIEZO1 expression analysis 
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We modeled in vitro our patients' genotypes by transient transfection of WT and 
mutant PIEZO1 expression plasmids into HEK293 cells. No significant differences 
between mutant and WT PIEZO1 mRNA were evident 72h post-transfection 
(Figure 4.11A). Similarly, immunoblot analysis of PIEZO1 confirmed equivalent 
expression of WT and mutant PIEZO1polypeptides (Figure 4.11B). 
 
 
Figure 4.11. Expression levels of PIEZO1 in Hek293 cells transfected with the mutants 
constructs. 
Panel A. PIEZO1 mRNA levels in cells over-expressing human PIEZO1 WT, PIEZO1 
Glu2492_Leu2493dup, PIEZO1 Arg1864His. Values are means +/- s.e.m. of three independent 
experiments. Panel B. Immunoblot showing PIEZO1 protein expression in cells over-expressing 
human PIEZO1 WT and mutants. β-actin is loading control. One of two similar experiments.  
 
4.3.5 Cation flux in PIEZO1 mutants 
Measurement of ouabain- and bumetanide-resistant net cation flux demonstrated a 
greater loss of cell K from both mutants PIEZO1-expressing cells than from WT 
PIEZO1-expressing cells (Figure 4.12). Of note, the presence in cis of both the 
mutations causes an increase of potassium efflux compared to the only 
E2492_L2493dup.  
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Figure 4.12. Panel A. Cell Rb+ content of cells over-expressing CDS of PIEZO1 WT and mutants (* p 
value <0.05 WT vs EV; ** p value <0.001 R1864H and E2492_L2493dup vs WT). Panel B. 
Extracellular K+ content in culture medium of the same cells described in B (* p value <0.05 WT vs 
EV; ** p value <0.001 R1864H and E2492_L2493dup vs WT). Values are means +/- s.e.m. of 3 
independent experiments.  
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5. Discussion  
 
This work take together three studies on three different ionic channels, all involved 
in the pathogenesis of erythrocyte defects caused by alterations in membrane 
transport.  
In this study we have reported three new mutations in the FP-disease gene 
ABCB6. FP had been described previously as a dominant condition, but, for the 
first time, we report two FP patients with homozygous or compound heterozygous 
mutations, both novel patterns of inheritance for FP. Of note, those patients 
homozygous and compound heterozygous for ABCB6 mutations showed higher 
plasma [K+] than heterozygous patients. Moreover, the compound heterozygous 
also exhibited a value of MCV higher than in other patients. FP inheritance patterns 
thus constitute a crucial part of patient diagnostic evaluation. 
ABCB6 variations are more common that previously predicted, as also reported for 
Lan- blood group carriers with ABCB6 nonsense mutations causing the ABCB6-null 
RBC phenotype. Koszarska and colleagues showed that screening of erythroid 
ABCB6 expression reveals an unexpectedly high frequency of Lan mutations in 
healthy individuals (Koszarska et al 2014). Indeed, in public databases (1000 
Genomes, NHLBI Exome Sequencing Project, Exome Aggregation Consortium) 
allele frequencies are 0.43% for V454A, 0.08% for R723Q and 1.5% for R276W. 
Moreover, the high frequency of ABCB6 variations in FP, including two FP patients 
found in a Cardiff blood donor cohort as recently described by Bawazir et al has 
clinical implications for blood transfusion screening and practice (Bawazir et al 
2014). Our own screening of 327 blood donors of different geographical and ethnic 
origin corroborates this observation, with the R276W mutation found in 0.3% of our 
cohort. Our analysis of potassium efflux from blood donor RBCs under blood 
banking storage conditions confirmed the cation leak as shown by FP patients. 
Refrigerated storage of blood of FP patients causes rapid loss of potassium, and 
the extracellular potassium content of bags of stored cells increases during 
storage. This is of little consequence for the majority of transfusions, since the total 
amount of potassium transfused is relatively small compared to the total blood 
volume of the recipient. In contrast, this extracellular potassium can have serious 
or fatal consequences for neonates and infants receiving whole blood transfusions 
of large volume proportionate to body size. Several such cases of whole blood 
transfusion in infants leading to cardiac arrest and death have been described (Hall 
et al 1993; Chen et al 1999; Baz et al 2002; Smith et al 2008; Lee et al 2014). 
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The ABCB6 FP mutants overexpressed in HEK-293 cells showed no difference in 
accumulation of mRNA or protein, or in peripheral membrane immunolocalization 
as compared to WT ABCB6, and as previously demonstrated for ABCB6 FP variant 
R375Q. Consistent with these findings, in silico modeled 3D structures of these 
mutant ABCB6 polypeptide dimers predicted modest structural alterations of 
transmembrane and cytosolic ATP binding domains in both inward- and outward-
facing conformations. Prediction of the consequences of these structural alterations 
to the cation leak process remain uncertain, since the relationship between the 
mutant cation leak and the (proposed but still debated) wild-type transport of 
porphyrins remains poorly understood. Future molecular dynamics simulation 
studies in a model lipid bilayer across microsecond time-scales will extend our 
understanding of the impact of these FP mutants on the structure, and possibly the 
function, of ABCB6. 
To further characterize the role of ABCB6 mutants, we tested the hypothesis that 
their expression could modify K+ transport in HEK-293 cells in a manner similar to 
the altered K+ efflux in FP RBC. We found that cells expressing each mutant 
variant tested exhibited increased potassium efflux compared to WT. Co-
expression in HEK-293 cells of the two mutant variants expressed by patient 
Cardiff in compound heterozygous form produced the highest value of potassium 
efflux among all tested mutants. These data demonstrated that the new mutations, 
whether homozygous or compound heterozygous, act at the cellular level as gain-
of-function mutations. 
Among ABC proteins, only the cystic fibrosis transmembrane regulator 
CFTR/ABCC7 itself is known to mediate ion channel function. However, several 
ABC proteins, in addition to CFTR, function as ion channel regulators (Higgins et al 
1995; Welsh et al 1992; Inagaki et al 1995), including the Kir6 KATP channel 
regulatory subunits, sulphonylurea receptors SUR1, SUR2A, and SUR2B31. The 
question remains whether ABCB6 FP mutant polypeptides generate intrinsic cation 
leak pathways in membranes of RBCs (or experimentally in HEK-293 cells), or 
might secondarily dysregulate one or more endogenous membrane cation 
permeability pathways in erythrocytes (or HEK-293 cells). The negative results 
obtained to date in our electrophysiological studies conducted in HEK-293 cells 
and Xenopus laevis oocytes expressing WT or mutant ABCB6 variants (not shown) 
encourage further consideration of dysregulated endogenous electroneutral (or 
low-level electrogenic) transporters as cation leak mediators in FP red cells or cell 
models of heterologous expression. 
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Regarding DHS a recent study has highlighted a novel DHS gene, KCNN4, 
encoding the widely expressed KCa3.1 Gardos channel, a Ca21-sensitive K1 
channel of intermediate conductance (Rapetti-Mauss et al 2015). We have 
presented here two additional DHS families with KCNN4 missense mutations, 
family NA with the recently described R352H mutation, and family WO with the 
novel mutation, V282M. Of note, the R352H mutation in family NA was a de novo 
event in patient II.3. We speculate that R352H could be a mutational hot spot, as it 
shares a typical CpG sequence, in which C>T and G>A mutations likely reflect 
deamination of methylated cytosine. 
The mild hemolytic anemia and elevated reticulocyte counts in the families 
described here presented with a milder phenotype than exhibited by the two 
recently described DHS families with the KCNN4 R352H mutation. The first patient 
described by Mauss et al presented with severe in utero anemia, requiring one in 
utero transfusion at gestational week 27 and three additional perinatal transfusions, 
with mild anemia and splenomegaly present at 4 years of age. The other previously 
described patient had moderate, transfusion-independent chronic hemolytic 
anemia from early childhood onward, and underwent a cholecystectomy. DHS 
caused by PIEZO1 mutations has also been associated with wide variation in 
clinical phenotype. Several modifier genes could affect the phenotype of DHS 
patients, including PIEZO1. Indeed, patients II.3 and III.1 exhibited several PIEZO1 
polymorphisms that might contribute to differences in their clinical phenotypes. Of 
note, splenectomy is contraindicated in PIEZO1-associated DHS because it is 
associated with severe thromboembolic events (Andolfo et al 2016). In contrast, 
splenectomy seems neither to predispose to thrombotic events nor to improve 
anemia in the small number of DHS patients reported to date with KCNN4 
mutations. We speculate that in PIEZO1-associated DHS patients, the presence of 
the mutated channel, also involved in cell–cell adhesion processes (McHugh BJ et 
al 2012; McHugh BJ et al 2010), might predispose to RBC aggregation with a 
reduced threshold for thrombus formation. Our patients showed changes in 
ektacytometry parameters similar to those of PIEZO1-associated DHS patients. 
Family WO showed a curve more left-shifted than Family NA, demonstrating 
greater dehydration potentially attributable to the distinct consequences of the two 
missense mutations The solvent-accessible KCNN4 R352 is modeled within the 
CaMBD2a section (aa 344-353) of the multi-site calmodulin binding domain, within 
electrostatic interaction distance of calmodulin E84 and of E363 of the adjacent 
KCNN4 protomer. Ca2+ ligation by KCNN4-bound calmodulin increases open 
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probability of the KCNN4 K+-selective channel pore to increase K1 efflux from the 
red cell. Engineered mutation of KCNN4 R352 to Cys moderately prolongs the 
channel inactivation time constant without substantial change in activation time 
constant (Andolfo et al 2015). Indeed, the KCNN4 R352H mutation found by 
Rapetti-Mauss et al. in two DHSt families displayed increased K1 channel activity 
secondary to 10-fold increased Ca2+-sensitivity and to delayed channel 
inactivation. The KCNN4 V282 residue mutated in family WO is modeled near the 
C-terminal cytoplasmic end of transmembrane span S6 of the pore-forming 
domain, suggested to both line the cytoplasmic-facing pore lumen below the P-loop 
selectivity filter, and to contribute to channel activation. V282 is predicted to lie at 
the narrowest point of the pore vestibule below the selectivity filter, and is 
evolutionarily conserved as far back as the D. melanogaster Shaker K1 channel. 
The engineered KCNN4 mutation V282W shortened the channel’s activation time 
constant without effect on the deactivation time constant, while also modestly 
increasing channel sensitivity to activation by intracellular [Ca++] (Bailey et al 
2010). Engineered substitution of V282 with hydrophilic residues locked the 
channel in the open state (Garneau et al 2010). Thus, the properties of engineered 
mutations in each of the two alleles found independently mutated in our two DHS 
families are consistent with predicted gain-of-function properties of the DHS-
associated KCNN4 mutations. However, neither of our DHS families exhibited 
pseudohyperkalemia, consistent with the previously described patients with 
KCNN4 R352H mutations (Rapetti-Mauss et al 2015). Biochemical data and T2* 
magnetic resonance indicate the presence of hepatic iron overload, previously 
described as an important complication of DHS (Andolfo et al 2016). This feature in 
a splenectomized patient further supports the role of dyserythropoiesis as reported 
for PIEZO1 mutation-associated DHS. KCNN4 expression gradually increased 
during erythroid differentiation of CD34+ cells and K562 cell lines, consistent with 
some role in erythroid maturation. Kcnn4 expression also increased during mouse 
embryonic development, possibly linked to its functions in many non-erythroid 
tissues, including the immune system, gut, bone, endothelial cells, heart, placenta, 
and pancreas (Maher et al 2003). Moreover, KCNN4 expression also increases 
during in vitro erythroid differentiation of murine ES cells (Vandorpe et al 1998). 
KCNN4 expression analysis in family NA showed that the R352H mutation did not 
impair its mRNA expression. Moreover, red cell membrane proteins involved in 
other RBC disorders, including AE1, ABCB6, and EPB72, were unaltered in their 
expression levels in family NA, consistent with an independent pathogenic 
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mechanism in KCNN4 mutation-associated hemolytic anemia. Moreover, apparent 
reductions in PIEZO1 protein abundance did not clearly cosegregate with the DHS 
phenotype. With this study we have expanded the cohort of DHS families with 
KCNN4 mutations, describing two previously undiagnosed families and one novel 
mutation. Future electrophysiological studies will investigate possible alterations in 
KCNN4 gating or ion selectivity that associated with the novel mutation V282M. 
Severely affected DHS patients with these KCNN4 mutations should be considered 
for treatment with the Gardos channel inhibitor, senicapoc (Ataga et al 2011). 
The collection of new cases of DHS has allowed us to perform the molecular 
characterization of seven DHS patients from two unrelated families both carrying a 
novel in frame duplication. One proband of the two families carried also a novel 
missense mutation in PIEZO1 gene. The functional study revealed the causative 
role of both novel mutations here described. Moreover, we demonstrated the 
phenotype-modifier role of the de novo mutation R1864H, in cis with the inherited 
duplication E2492_L2493dup on the occurrence of severe phenotype observed in 
the proband of family 2. This finding highlighted the importance to study the effect 
of multiple modifier PIEZO1 variants on the genotype-phenotype correlation, 
considering also that PIEZO1 gene is a highly polymorphic locus. Moreover, it 
opens the field of study of modifier variants in other genes involved in iron 
metabolism and erythroid transport that could explain the variable expressivity 
observed in this condition. 
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6. CONCLUSIONS 
 
The research effort allowed us to demonstrated the pathogenetic mechanism of 
FP, to find another causative gene of DHS, KCNN4, and finally to characterize new 
mutations of PIEZO1 gene. 
Our findings demonstrate that both heterozygous and homozygous missense 
mutations in ABCB6 lead to increased efflux of cellular K+ from HEK-293 cells, a 
property shared with RBCs of FP patients. Screening for the most frequently found 
ABCB6 variant, R276W, confirmed that patients with FP are relatively common in 
the blood donor population. Storage of FP blood can cause a significant increase in 
whole blood K+ levels, with serious clinical implications for neonates and infants 
receiving large-volume transfusions of whole blood. For these reasons, we endorse 
the proposal to conduct genetic screening for ABCB6 FP mutations among 
potential blood donors, especially when whole blood is needed. Finally, 
investigation of ABCB6 may contribute to our understanding of other pathologies of 
red blood cell hydration, such as sickle cell anemia. 
Hyper-activation of either PIEZO1 or the Gardos channel leads to similar clinical 
phenotypes, strongly suggesting that both channels act together to shrink RBC 
volume under mechanical stress. It is likely that hyperactivity of the Gardos channel 
is responsible for K+ and water efflux, either because of an activating mutation in 
Gardos channel or because of mutations in PIEZO1 that would increase 
intracellular Ca2+ level and subsequently activate Gardos channel. However, 
PIEZO1 is more selective to K+ than it is to Ca2+ and mutations that prolong the 
conductive state of the channel are expected to increase the K+ leak through 
PIEZO1, independent of an eventual activation of the Gardos channel due to 
increased Ca2+ permeability. Further research on ion selectivity of mutated 
PIEZO1 is necessary to fully understand its involvement in red cell dehydration. 
Although both the PIEZO1 and Gardos channels are expressed in other tissues, 
dysfunction of these proteins leads to defects only in circulating cells such as RBC. 
This suggests that compensatory mechanisms might take place specifically in the 
other tissues where these proteins are expressed. Other unsolved questions are 
the development of iron overload and the possible link to the alteration of ionic 
content and the occurrence of thrombosis event after splenectomy.  
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